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The protozoan parasite Trypanosoma brucei, a causative agent of human and animal
trypanosomiasis, evades host immunity through antigenic variation of its variant surface
glycoprotein (VSG) coat. During infection, the VSG coat elicits a robust antibody response, but
the parasite escapes antibody-mediated clearance by repeatedly accessing its large genomic VSG
repertoire and switching expression to antigenically distinct VSGs. Much of our knowledge of
the process of VSG switching and the extent of VSG diversity has come from genetic analyses,
but deep understanding of the T. brucei host-pathogen interface also requires examination of
these topics at the protein level. In this thesis, I describe two protein-based studies of the VSG
coat that reveal factors influencing trypanosome evasion of the host antibody response.
First, I discuss my examination of the dynamics of VSG coat replacement following a
genetic VSG switch, and the impact of this process on the parasite’s ability to escape the
escalating host antibody response. Using a flow cytometry-based measurement strategy, I
evaluated the rate of VSG replacement at the trypanosome surface, and showed that full coat
replacement requires several days to complete. I then demonstrated through in vivo infection
assays that parasites undergoing coat replacement are only vulnerable to clearance via early IgM
antibodies for a limited time. Finally, IgM binding analyses and molecular modeling indicated
that IgM loses its ability to mediate trypanosome clearance at unexpectedly early stages of coat
replacement based on a critical density threshold of its cognate VSGs on the parasite surface.

In the second part of this thesis, I describe a collaborative body of work examining the
biochemical features of VSG3 (also termed MITat1.3 and VSG224) and their relevance to
parasite interactions with host immunity. The crystal structure of VSG3 was solved, and analysis
of the high-resolution structure revealed a glycan of a form previously unidentified in T. brucei,
which was centrally located within a region likely to be involved in VSG-antibody interactions.
Subsequent mouse infection and antibody binding analyses demonstrated that this VSG
modification increases parasite virulence and facilitates evasion of host antibodies.
Together, these studies increase our understanding of T. brucei infection dynamics and
reveal that additional layers of VSG diversity can affect parasite immune evasion. The
identification of an antigen density threshold for in vivo IgM functionality may also inform other
systems in which IgM plays a crucial role. These results affirm that much remains to be learned
about the interactions of the VSG coat with the host antibody response. Further examination of
VSG biochemical diversity and the VSG-antibody interface may provide additional insights into
T. brucei pathogenesis and potentially carry implications for other host-pathogen interactions or
immune interactions in general.
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Chapter 1
Introduction
1.1

African trypanosomes and trypanosomiasis
Human African trypanosomiasis (HAT), also known as African sleeping sickness, is an

infectious disease that affects large regions of sub-Saharan Africa. It is transmitted between hosts
by the bite of the tsetse fly (Glossina spp.), and the habitat range of this vector defines the
geographical distribution of HAT endemic regions1. The disease can also transmit between
different mammalian species, and infections in non-human hosts are known as animal African
trypanosomiasis (AAT) or nagana2. In humans, the disease is almost invariably fatal if untreated1.
HAT and AAT are caused by a group of unicellular, protozoan parasites known as
African trypanosomes. Only two subspecies of African trypanosome, Trypanosoma brucei
gambiense, and T. brucei rhodesiense are capable of infecting humans, and infections with both
of these subspecies proceed in two stages. First, the parasite inhabits the blood, lymph, and
interstitial fluids of its host, and recent evidence suggests it can also invade fatty tissues3.
Symptoms at this stage are non-specific to trypanosomiasis (e.g. intermittent fever, aches), which
complicates early diagnosis. In the second stage, the parasite crosses the blood-brain barrier and
invades the central nervous system. First stage symptoms persist, accompanied by additional
neurological symptoms such as psychiatric disorders and disturbance of the sleep cycle
(originating the name “African sleeping sickness”), which intensify as the disease progresses.
Drug treatment is possible at both stages, but the comparatively milder drugs used to treat first
stage disease cannot cross the blood-brain barrier, requiring the use of different drugs for second
stage treatment, which are more toxic and difficult to administer1,4,5. The time course of HAT
pathogenesis varies depending on the T. brucei subspecies causing the infection. T. b. gambiense,
1

which is found in western and central Africa, causes a chronic, slowly progressing infection
lasting up to several years. T. b. rhodesiense, found in eastern and southern Africa, typically
causes acute infection, progressing to second stage within weeks, and death within 6 months1.
The vast majority (~97%) of HAT cases are caused by T. b gambiense6.
HAT was a cause of significant mortality through much of the 20th century, but control
measures (including improved diagnosis and disease surveillance, access to treatment, and vector
control) have dramatically reduced the spread of human infection in recent years, with the
number of new reported HAT cases falling from ~40,000 in 1998 to only 2804 in 20151,5.
However, the number of reported cases is considered to represent only a fraction of the actual
number of infected individuals, and ~60 million people are still estimated to be at risk of
infection 4,7. Furthermore, the utility of current HAT treatment options is increasingly threatened
by the development of drug resistance, necessitating continued efforts to discover novel antitrypanosomal drugs8.
A more diverse set of African trypanosomes infect animal hosts, including both humaninfectious T. brucei subspecies, another subspecies T. brucei brucei, and other members of the
Trypanosoma genus, T. congolense, T. vivax, T. evansi, and T. equiperdum 2 (although recent
phylogenetic analyses suggest that T. evansi and T. equiperdum, which have long been
considered individual species, may more accurately be described as T. brucei subspecies9). In
contrast to the human-infectious trypanosomes, many animal-infectious trypanosomes, including
T. vivax, T. evansi, and T. equiperdum, have evolved transmission mechanisms through vectors
other than the tsetse fly. These adaptations have allowed these trypanosomes to spread outside of
Africa into South and Central America, Asia, and parts of southern Europe. The animalinfectious trypanosome species show diversity in predominant host species affected, disease
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pathogenicity, vector, and geographical distribution, and collectively they impose a significant
burden on global agricultural economies due to death and morbidity of cattle and other livestock2.
In Africa alone, the annual economic losses due to AAT are estimated at ~1-5 billion USD4,10.
Additionally, these animal infections may function as a reservoir for human-infectious parasites,
threatening efforts to eradicate African trypanosomiasis as a public health concern11.
The reason many animal-infectious trypanosomes cannot infect humans is that human
blood contains two innate immune complexes, trypanosome lytic factor 1 (TLF-1) and TLF-2,
which have trypanocidal properties12-14. On rare occasions, humans can become infected with
animal-infectious parasites15. In some cases the individual’s susceptibility to these infections can
be attributed to mutations in TLF components16, but in other cases the cause of susceptibility is
unknown17. Human-infectious T. brucei gambiense and T. brucei rhodesiense have both evolved
mechanisms of inhibiting the action of the TLFs18-22, and the possibility remains that additional
trypanosome species may evolve resistance mechanisms which allow transfer of these infections
to humans. While the animal-infectious African trypanosome species are all clearly important to
global agriculture and animal health, this thesis will be primarily focused on T. brucei, the
species more relevant to human infection and the most intensely studied of the African
trypanosomes.
1.2

T. brucei life cycle and transmission
T. brucei inhabits extracellular spaces within both the vector and the mammalian host. In

order to survive in each of these environments and successfully transfer between hosts, the
parasite undergoes a sequence of life cycle stages with adaptive morphologies, proliferative
capacities, and gene expression patterns. The T. brucei life cycle begins when an infected tsetse
fly takes a blood meal, and metacyclic form parasites are transferred into the host bloodstream
3

through the fly’s saliva. These trypanosomes first differentiate into their slender bloodstream
form. Slender form parasites are highly proliferative, and divide rapidly until a quorum sensing
mechanism initiates transformation of some parasites into a non-proliferative stumpy
bloodstream form23,24. The mixture of slender, stumpy, and intermediary (transitioning from
slender to stumpy) bloodstream forms is known as “pleomorphism”. Recent T. brucei field
isolates and some lab strains are capable of pleomorphism, but many lab adapted cell lines
(including the Lister 427 cell line used for experiments presented in this thesis) are generally
thought to have lost the ability to differentiate to stumpy forms25. During infection, the growth
arrest of stumpy forms helps prevent rapid host death from slender form overgrowth, which
would threaten subsequent parasite transmission26,27. Stumpy form cells are also especially
adapted for reuptake into the tsetse fly midgut during a subsequent blood meal. They are resistant
to the acidic environment of the midgut28, and their surface receptor profiles and stage of cellcycle arrest prime them for rapid differentiation into the next life cycle stage, the procyclic form,
upon receiving midgut environmental cues29,30. Procyclic form trypanosomes develop in the fly
gut, sequentially expressing a set of surface proteins called procyclins that protect the parasite
from digestive enzymes31. These parasites migrate towards the salivary glands, differentiate
again to the epimastigote stage, and attach to the salivary gland epithelium. At this point,
epimastigotes can undergo meiosis and sexual exchange of genetic material32,33. Finally, the
parasites mature again to the mammalian-infectious metacyclic forms, and reside in the salivary
glands until transferring to another host.
1.3

Antigenic variation - the variant surface glycoprotein (VSG) coat
Because T. brucei lives extracellularly within its mammalian host, it is continually

exposed to attack from host immune factors. Long-term parasite persistence in this environment
4

is made possible via antigenic variation of the dense, variant surface glycoprotein (VSG) coat
that covers the trypanosome in its bloodstream form. Each parasite expresses one VSG gene at a
time from a genomic repertoire containing thousands of VSG genes 34, and is densely coated with
~107 VSGs35,36. VSGs are highly immunogenic. During infection, the host develops potent VSGspecific antibodies that mediate trypanosome clearance, but a minority of parasites evade
clearance by accessing their VSG repertoire and changing their coats to antigenically distinct
VSGs35,37 in a process known as VSG “switching”. These switched parasite populations then
expand within the host until they are cleared, after which additional populations expressing
distinct VSGs emerge again. This cyclical process results in characteristic waves of parasitemia
occurring at approximately 5-8 day intervals during infection, with parasite suppression in sync
with and mediated by the development of repeated primary, VSG-specific antibody responses37-41.
All species of African trypanosomes express VSG coats and use antigenic variation as a
survival strategy, although there are differences between species in the evolution of the genetic
VSG repertoire9,42, and there appear to be some species-dependent differences in the genetic
mechanisms regulating VSG diversification43. Other pathogens also utilize similar mechanisms
of antigenic variation to evade host immunity, including Giardia lamblia, which alters its variant
surface protein (VSP) coat, and Plasmodium falciparum, which alters the PfEMP1 proteins it
transports to the surface of infected erythrocytes44,45. Examination of antigenic variation and the
host-pathogen interface in T. brucei may thus provide insights that can be applied to additional
clinically relevant pathogens.
The work presented in this thesis will focus on the T. brucei host-pathogen interface, and
particularly on host antibody interactions with the VSG coat. The remaining sections of this
introduction will therefore predominately describe the current knowledge of the VSG coat,
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including its structure, functional attributes, mechanisms of diversification, and interactions with
host immunity.
1.4

Structure of the VSG coat and basis of immune shielding function
VSGs are large surface proteins (50-60 kDa) that are bound to the exterior face of the T.

brucei plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. They are the most
abundant protein in bloodstream form T. brucei, accounting for about 10% of the total protein
content of the cell, and at least 95% of the protein on the cell surface 46-48. All VSGs consist of
two domains: a highly variable N-terminal domain (350-400 residues), and a smaller, more
conserved C-terminal domain (20-40 residues) to which the GPI anchor is attached49,50. The two
domains are connected by a flexible linker51. Despite the fact that VSG N-terminal domains
typically share low sequence homology, early structural analyses of the N-terminal domains of
two VSG variants revealed that the VSGs had a conserved structural motif50,52: the VSGs formed
homodimers, and each monomer was structured in a two-lobed, "dumbbell" arrangement, with
the "top" (facing away from the pathogen) and "bottom" regions separated by an elongated 3helix bundle. However, the sequences and specific architectures of each VSG varied
considerably, in accordance with their function as antigenic variants. Each VSG also contains at
least one N-linked oligosaccharide53, and in all known structures these glycans are linked to
residues in the bottom lobe of the N-terminus.
Our current model of the larger structure of the VSG coat has been formed and refined by
a series of measurements and observations spanning the past several decades. Early crosssectional electron microscopy images of the trypanosome plasma membrane showed a dense
exterior coat with a thickness of 12-15nm54. This measurement, along with later determinations
of VSG dimensions (derived from VSG crystal structures50,55,56) provided evidence that
6

individual VSG homodimers extend vertically from the cell surface. Further calculations based
on estimates of the surface area of a vertically-oriented VSG homodimer, the total trypanosome
cell surface area, and the VSG per cell copy number revealed that the VSGs are extremely tightly
packed, physically occluding the vast majority of the cell surface35,36,48. Most recently, a study
found that VSGs can adopt two conformations based on flexibility in the orientations of the Cterminal domain and linker region51. VSGs were identified in either a taller and thinner “compact”
structure, or a shorter, more expansive “relaxed” structure. The authors concluded that shifting
between these two conformations allows the VSG coat to accommodate variations in the total
amount of surface VSGs while still maintaining occlusion of the plasma membrane.
Dense VSG packing is crucial to the immune shielding function of the VSG coat. Studies
using VSG-specific monoclonal antibodies have shown that only a portion of antibodies
generated against soluble VSGs are able to bind VSGs expressed on living trypanosomes49,57-59.
The common interpretation of this phenomena is that close packing between VSGs limits
antibody access to surfaces other than the highly variable “top” of the molecule, leaving the more
conserved C-terminal domain and many epitopes of the N-terminal domain hidden by steric
hindrance. However, it has also been suggested that some antigenic differences between soluble
and membrane-bound VSG may be due to conformational changes in the soluble VSG resulting
from delipidation of the VSG anchor60. Studies attempting to map the epitopes of individual
monoclonal antibodies have not conclusively determined how much of the VSG N-terminus is
accessible (reviewed in49). One notable study, which mapped the binding epitope of an IgG class
antibody using chimeric VSG constructs, found that the antibody recognized a region on the
“lower” lobe (proximal to the parasite) of the N-terminus61. This result demonstrates that at least
in some cases, much of the VSG N-terminal domain may be accessible. In contrast, a study
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examining polyclonal antisera raised against two VSG C-terminal domains found no binding
against live trypanosomes62, suggesting that these more conserved domains are indeed protected
from immune recognition. It is often stated that the VSG coat also hides other invariant surface
antigens from immune surveillance, and this is likely true for membrane proteins with small
extracellular domains49. However, antibodies recognizing invariant surface proteins with large
extracellular domains have been detected in the antisera of mice and humans infected with T.
brucei63,64. Still, most of these antibodies do not effectively bind intact trypanosomes (suggesting
that many of the epitopes are still occluded by the VSG coat), and antibodies elicited against
invariant proteins do not produce protective immunity49,63.
The VSG coat also protects the parasite from innate immune components. While
alternative complement pathway activation and binding of complement components to the
trypanosome surface have been identified following incubation in human serum, the complement
cascade does not proceed to parasite lysis65. A report showing that a T. congolense cell line
lacking a VSG coat, as well as procyclic forms of T. congolonse and T. brucei brucei could all be
lysed by human complement provided evidence that the VSG coat itself may be necessary for
restricting procession of the complement cascade66, but the molecular basis of this restriction is
unknown. Complement mediated trypanosome lysis can occur, however, through antibody
binding and activation of the classical complement pathway67.
1.5

Fluidity and recycling of the VSG coat
The VSG coat is a highly fluid array, and individual VSGs are free to rapidly diffuse

throughout the plasma membrane. The VSG lateral diffusion coefficient ensures complete
randomization of the entire VSG coat (via diffusion-based rearrangement alone) in a period of
about 40 minutes68. Additionally, the VSG coat is in a constant state of flux, with individual
8

VSGs constantly being shuttled on and off the cell surface. All endo- and exocytosis in T. brucei
occurs at the flagellar pocket, a specialized structure that makes up 2 % of the total surface
membrane, and is situated at the base of the flagellum at the posterior end of the cell. VSGs at
the flagellar pocket are internalized by endocytosis in clathrin-coated vesicles69 and delivered to
RAB5-positive early endosomes. The vast majority are then sorted to RAB11- positive recycling
endosomes (directly or via RAB7-positive late endosomes) where they are delivered back to the
flagellar pocket and reemerge onto the cell surface70-73. Roughly 9 % of the total cellular VSG
content is in this internal recycling pathway at steady state. Despite the high abundance of
surface VSGs, this process is rapid and efficient. The entire surface coat goes through one round
of internalization and redistribution to the cell surface in approximately 12.5 min, indicating that
the VSG coat is more efficiently randomized by this process than by lateral VSG diffusion73.
It has long been observed that live trypanosomes rapidly redistribute surface- bound
antibody to the flagellar pocket57. VSG and bound antibody are then internalized together, but
upon internalization, the antibody is separated from the VSG, transported to the lysosome, and
degraded71,74. It is not entirely clear how VSGs are specifically sorted from other proteins in the
endosome, but the current model suggests that this selection is based on default sorting of GPIanchored proteins to the recycling pathway70,72. VSG recycling thus provides a mechanism for
rapid clearance of host antibodies from the trypanosome surface. Trypanosomes have been
demonstrated to fully remove a single layer of surface-bound IgG in 120 s at 37 C75, far faster
than the rate of internalization of the VSG coat. This increased antibody clearance rate has been
accounted for by the influence of hydrodynamic forces created by parasite motility. Beating of
the trypanosome flagellum produces forward motion, causing bound antibodies to act as
“molecular sails,” which preferentially drives VSG–antibody complexes to the posteriorly
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located flagellar pocket75. Overall, the high rate of endocytosis and surface coat recycling
appears to be another adaptation for immune evasion in the mammalian host.
Still, the relative contribution of surface antibody clearance to immune evasion has not
been determined. The notion that this process is, in fact, an immune evasion strategy is supported
by observed differences in endocytosis rates between bloodstream form trypanosomes and those
in other life cycle stages, which are not subject to similar immune pressure. Bloodstream form
trypanosomes induced to differentiate to the tsetse fly midgut-inhabiting procyclic form show
downregulation of components of the endocytic pathway and a concurrent tenfold reduction in
endocytosis rate76. One study has indicated that mice infected with trypanosomes with a motility
defect that prevented the internalization of bound antibody did not have a survival advantage
over mice infected with motile trypanosomes77. However, the trypanosomes used for these
experiments were derived from the highly virulent Lister 427 strain, and all mice succumbed to
infection within 2 weeks. Thus, the importance of antibody internalization has not been
addressed in a model of chronic infection. It has also been proposed that antibody internalization
may be more crucial to preventing effector functions of antibodies recognizing invariant surface
proteins, rather than those recognizing the VSG coat49.
1.6

VSG release via the GPI phospholipase C
In its bloodstream form, T. brucei expresses an endogenous phospholipase (GPI

phospholipase C; GPI-PLC) which can hydrolyze the GPI anchor of surface VSGs, releasing
membrane-bound VSG into solution78. The GPI-PLC is activated following cell death or stress,
and it rapidly releases the entire VSG coat from the plasma membrane within a period of a few
minutes79,80. It is unclear whether the GPI-PLC also releases VSG from live cells: the enzyme is
constitutively expressed and always localizes to the plasma membrane81, and there is evidence
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that VSG is shed at a low rate from live cells82,83, but no evidence that this type of shedding is
catalyzed by the GPI-PLC. GPI-PLC knockout (GPI-PLC-/-) cell lines cannot shed VSG, and
maintain intact coats following cell death or stress84,85. The lack of GPI-PLC does not affect
parasite virulence in the monomorphic Lister 427 T. brucei strain84, but was shown to slightly
decrease parasite virulence in another cell line (EATRO 1125)85.
1.7
1.7.1

The genetic basis of VSG expression and VSG switching
VSG monoallelic expression
VSG genes are exclusively expressed from one of ~15-20 telomeric Bloodstream

Expression Sites (BES). All BESs contain VSG genes, but only one is BES is transcriptionally
active at any given time. The BESs are highly homologous to one another, each having a set of
similar features: a single promoter located at the telomere-distal end, followed by a group of
expression site associated genes (ESAGs), a stretch of repetitive DNA known as the 70 base pair
(70bp) repeats, and finally the VSG gene at the telomere-proximal end86,87. BESs vary in the
number and type of ESAG genes they contain, and some BESs also contain multiple 70bp repeat
regions and incomplete VSG “pseudogenes” upstream of the active VSG. The entire BES is
expressed in a polycistronic pre-mRNA transcript, which is later spliced into individual mature
mRNA transcripts with each gene flanked by a common 5’ splice-leader sequence and 3’ poly-A
tail88-90. Interestingly, while mRNA is exclusively transcribed by RNA polymerase (pol) II in
most eukaryotes, the active T. brucei BES is transcribed by RNA pol I (which typically only
transcribes ribosomal RNA) 91,92.
The molecular mechanisms underlying the maintenance of monoallelic expression
are incompletely understood, but nuclear localization and chromatin state appear to play a major
role. The active BES is transcribed from an extranucleolar site known as the expression site body
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(ESB) 93, in which chromatin is unstructured and depleted of nucleosomes94,95. A recently
identified protein called VEX1 localizes to the ESB and can regulate allelic exclusion96, but its
mechanism of action is unknown. It is also unclear how the ESB forms or how a given BES is
chosen for inclusion. There is a great deal of evidence that the silencing of inactive BESs is at
least partially mediated by chromatin state. RNAi screens have identified a number of genes that
are required for repression of silent BESs, and most of these encode chromatin remodeling or
histone modifying proteins (reviewed in97). Telomeric silencing also appears to play a role, as
RNAi knockdown of the telomere-associated protein RAP1 also leads to derepression of silent
BESs98.
1.7.2

The genomic VSG repertoire
The VSGs located in BESs represent a tiny fraction of the entire genomic VSG

repertoire. The most completely characterized T. brucei genome is that of the Lister 427 strain of
T. brucei brucei, which has been found to contain more than 2,000 VSG genes34. The VSG
repertoires of other T. brucei subspecies (and other African trypanosome species) are less well
characterized, but appear to be of comparable size42. In T. brucei, the majority (~80%) of the
VSG-encoding sequences are incomplete genes or pseudogenes, though these sequences can still
contribute to antigenic variation (discussed in section 1.7.4). Apart from the BESs, VSGs are
located throughout the genome within the 11 megabase chromosomes, several intermediate
chromosomes (typically 1-7), and ~100 minichromosomes34,99. Non-BES VSGs are located
within internal arrays in the larger chromosomes, while those in minichromosomes are
subtelomeric.
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1.7.3

Mechanisms of VSG switching
There are two genetic mechanisms by which trypanosomes can undergo a VSG switch:

(1) Transcriptional switching (also known as in situ switching) occurs when the active BES is
silenced, and another BES is transcriptionally activated, and (2) Recombinatorial switching
occurs when a VSG from elsewhere in the genome is copied or swapped into the active BES.
Transcriptional switching only allows expression of those VSGs that are located within BESs
(14-19 VSGs), while recombinatorial switching allows access to the entirety of the genomic VSG
repertoire. Thus, recombinatorial switching is far more important for the maintenance of longterm infections, in which expression of many VSGs is required for continual evasion of host
immunity. Measurements of the relative frequencies of transcriptional and recombinatorial
switching have varied considerably between studies, but recombinatorial switching is generally
considered to be the dominant mechanism100-104.
Neither the mechanism by which transcriptional switching occurs nor the conditions that
trigger this type of switch are well characterized. Transcriptional switching must involve
chromatin remodeling as the active BES is excluded from the ESB and replaced with another
BES, but the molecular basis of this process is unknown. One study demonstrated that artificial
inactivation of the active BES (via a Tet repressor) triggered a transcriptional switch105. This
suggests that loss of transcription of the VSG gene or some other BES component may signal a
transcriptional switch, but again, does not inform the mechanism or how this may occur in a
natural setting.
The mechanisms of recombinatorial switching are comparatively better understood, and
this type of switch can proceed in several ways. In telomere exchange (TE), a crossover event
occurs between two chromosome ends, resulting in the active VSG swapping locations with a
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subtelomeric silent VSG106. In duplicative gene conversion (GC), a DNA region containing a
silent VSG is copied into the active BES, and the previously active VSG gene is lost from the
genome. GC is typically mediated by homologous recombination (HR), a DNA repair
mechanism that is activated following a double strand DNA break (DSB). HR can occur via
junctions at two homologous regions flanking the original and replacement VSGs, or via a single
upstream homologous region with DNA replacement proceeding through the telomere (also
known as break-induced replication (BIR))97. Studies have demonstrated reduced switching
frequency in strains lacking HR-related proteins, including the homologous strand exchange
protein RAD51107, BRCA2 (which mediates RAD51 function) 108, and a RAD51 paralogue109,110.
However, RAD51-independent GC switching also occurs, and this is likely mediated by a
secondary DSB repair process called microhomology-mediated end joining111,112.
GC switching can be induced by artificially introducing a DSB in the active BES, and
switching efficiency increases substantially when this break occurs near the 70bp repeat
region112,113. 70bp repeats are found upstream of more than 90% of genomic VSGs and have been
demonstrated to be crucial sites of homology for allowing access to most of the VSG
repertoire43,114. GC switching can also occur in trypanosome lines in which the 70bp repeats have
been deleted at the active BES, but in these cases switching is restricted to VSGs in other BESs
where regions of homology can still be found43,115. In natural settings, double strand DNA breaks
have been proposed to occur in the active BES due to errors in the procession of DNA
replication machinery and inherent fragility of subtelomeric genomic locations, with the 70bp
repeats representing a particularly susceptible region103,112,113,116,117. Still, the possibility remains
that the trypanosome may express factors, such as an unidentified endonuclease, that promote
switching in a targeted fashion. It is also unclear whether regulation of VSG switching is purely
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stochastic or whether environmental stimuli (e.g. host-dependent factors) affect switching
frequency, but the fact that switching occurs in vitro suggests that there is at least some
stochastic element to the process118,119
1.7.4

Mosaic VSGs
Most of the genomic VSG repertoire consists of incomplete VSG pseudogenes34, and these

gene segments contribute to T. brucei antigenic variation by recombining with one another or
with complete VSGs to generate functional “mosaic” VSGs. Mosaic VSGs are formed by
segmental GC events, and single mosaics can originate from as many as four donor
pseudogenes120-123. Donor sequences contributing to the same mosaic typically share substantial
homology (as would be expected for mosaic formation mediated by HR), but in some unusual
cases the borders of segmental GC events share little or no apparent homology120. Many aspects
of mosaic formation are uncharacterized, including whether it is a directed or stochastic process,
whether it occurs in the active BES or elsewhere in the genome, and when it occurs during
infection. However, one study37 showed that three mosaic genes were not detectable within a
parasite population during infection until trypanosomes actively expressing those VSGs emerged,
suggesting that at least in some cases formation occurs shortly before expression. Overall,
mosaic VSGs appear to contribute to antigenic variation in a manner that is greater than the sum
of their parts, as mosaics with substantial sequence similarity can still be antigenically distinct
from one another120.
1.7.5

Rates of switching
In lab-adapted cell lines, VSG switching occurs at a rate of 10-5 - 10-6 cells per population

doubling (C/PD) 113,118,119,124. However, these rates may drastically underestimate the frequency of
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switching in natural infections, as switching frequencies as high as 10-3 C/PD have been
measured in recent field isolates125. Interestingly, lab adapted cell lines have been shown to
increase switching rates 100-1000 fold following passage through the tsetse vector, suggesting
that switching frequency might be affected by environmental cues or differentiation between life
cycle stages126.
1.7.6

Dynamics of VSG expression in vivo
Several studies have demonstrated that VSGs are expressed in a probabilistic

order during infection41,127-129. The order appears to be related to genomic location, as expression
of BES VSGs typically occurs early in infection, followed by minichromosomal VSGs, and
finally VSGs from internal arrays41,129. The mechanism underlying this pattern is unknown, but a
number of factors may contribute. BES VSGs can be activated by both transcriptional and
recombinatorial switching, and the high homology between BESs87 gives many potential
locations for HR between these sites. Further, BESs contain complete VSG genes87, and a
disproportionally high percentage (85%) of minichromosomal VSGs are also complete, as
opposed to only ~20% in the VSG repertoire as a whole34. Trypanosomes switching to these
complete, functional VSGs would presumably have an early selective advantage. Conversely,
many chromosome internal VSGs are incomplete and can only be accessed by mosaic formation,
which is evident at much greater frequency late in infection120,123. The prevalence of mosaic VSGs
late in infection is likely a consequence of the parasite’s need to generate additional antigenic
diversity once the existing repertoire has been exhausted122.
Mugnier et al.37 analyzed the diversity of VSGs expressed within trypanosome
populations at varying time points throughout several T. brucei infections. Trypanosome
populations showed highly diverse VSG expression at each time point, with as many as 83 VSGs
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expressed concurrently within a single infection. However, within the first 30 days of infection
roughly half of the VSGs were expressed only transiently, never comprising as much as 1% of
the total population. Most VSGs that appeared only transiently in one infection comprised large
portions of the population in another infection, suggesting that the discrepancy did not result
from inherent VSG “fitness”. The authors proposed that VSG cross-reactivity was a potential
cause of this phenomenon, such that a VSG’s fitness might depend on whether it were
antigenically similar to a VSG the host had seen before. If that were true, the high diversity of
VSG expression would likely be necessary for sustained infection: each switched population
might need to express a multitude of VSGs to ensure that at least one is suitable for the immune
environment, despite the fact that this high diversity exhausts the available VSG repertoire more
quickly.
1.8
1.8.1

T. brucei interactions with host immune factors
The B cell response
VSG-specific antibodies are the key functional components in the immune response to T.

brucei, as they are the only immune factors that mediate clearance of peaks of parasitemia.
Studies in which B cell-deficient mice were infected with pleomorphic T. brucei showed that the
parasites expanded exponentially within the host before reaching a consistently high level of
parasitemia that increases very slowly until mouse death130,131. As the authors of these studies
noted, the stabilization of parasitemia is at least partially due to parasite differentiation to nonproliferative stumpy bloodstream forms (see section 1.2). T. brucei can be activate B cells to
produce VSG-specific antibodies via T cell-dependent (TD) and T cell-independent (TI)
pathways132. TD B cell responses are typical against protein antigens, but the ability of T. brucei
to stimulate a TI B cell response is likely based on the density and regularity of the VSG coat133.
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Soluble VSG and VSG coats disrupted by formalin fixation do not stimulate TI responses, and
different VSG coats stimulate TI responses with varying efficiency132.
Of all the immunoglobulin (Ig) classes, VSG-specific IgM plays a dominant role in
mediating trypanosome clearance. One study which followed IgM and IgG titers during T. brucei
infection showed that IgM was detectable during the first peak of parasitemia, but the
parasitemia peak was already cleared before IgG was detectable40. Furthermore, the rough 5-8
day periodicity of parasitemia waves37,38,41 aligns with the expected time frame of successive IgM
responses. Still, the importance of IgM in trypanosome clearance has been the subject of some
controversy. Experimental infections in IgM-deficient (but IgD-expressing, and thus also termed
"IgD-only") mice134 have shown mild phenotypes in parasitemia progression as compared to
infections in wild-type mice, prompting the conclusion that IgG may be more responsible for
parasite suppression130,131. However, the IgM-deficient mice generated compensatory IgD
antibodies (normally absent in wild-type mice) with the same dynamics as a typical IgM
response. Thus, an alternative explanation for these results is that trypanosome clearance is
mediated by the earliest arising antibody response, and that IgD is largely capable of performing
this function in place of IgM.
Antibody-mediated parasite clearance occurs in two ways: complement-mediated
parasite lysis, and opsonization by phagocytes. Complement-mediated trypanosome lysis does
not occur in the absence of VSG-specific antibody (discussed in section 1.4); it is dependent on
antibody-mediated activation of the classical complement pathway67. Parasite opsonization is
predominately carried out by macrophages in the liver, with smaller contributions from
macrophages in other locations such as the spleen40,135. Studies examining whether opsonization
requires deposition of complement components (for complement receptor-mediated uptake), or
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whether it can be mediated by antibody (Fc) receptors alone have produced conflicting results.
Macaskill et al.136 reported that depletion of complement component C3 reduced trypanosome
clearance by hepatic macrophages in passively immunized mice, while Dempsey et al.40 depleted
C3 by the same method in directly immunized mice and saw no change in parasite clearance.
1.8.2

Innate immunity
In addition to human innate trypanolytic agents TLF-1 and 2, which protect against many

African trypanosome species (discussed in section 1.1), other innate immune factors also
influence the progression of T. brucei infection. Very early in infection, trypanosome-derived
factors activate macrophages to produce nitric oxide and pro-inflammatory cytokines such as
TNF-a, IL-1, IL-6, and IL-12. Of these, TNF-a appears to play a particularly important role in
limiting parasite growth and maximum parasitemia levels137-139. However TNF-a also has
negative effects, as it has been shown to suppress T cell proliferation during infection140. T.
brucei DNA appears to be an important factor in inducing macrophage activation, and this
occurs in a Toll-like receptor 9 (TLR9)-dependent manner141,142. Mice deficient in TLR-9 and
MyD88 (an important molecule in TLR signaling) showed increased parasitemia levels and
decreased survival time following T. brucei infection142. The VSG GPI anchor also signals
macrophage cytokine production143, and it is likely that other trypanosome-derived factors
stimulate innate immune responses as well142.

1.8.3

The T cell response
While T cell help is known to be important for the development of optimal VSG-specific

antibody responses132, and purified VSG can produce protective immunity35, T cells isolated from
T. brucei-infected animals typically show poor proliferation in response to VSG144,145. However,
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VSG-specific T cells have been identified. One study demonstrated that a set of VSG-specific T
cells only recognized peptides from variant N-terminal portions of the VSG (rather than
conserved C-terminal regions), suggesting that antigenic variation might affect T cell recognition
in addition to B cell and antibody recognition146.
T cells also produce of IFNg, which has been shown to be a crucial factor in host
resistance during T. brucei infections147. IFNg is predominately produced by CD4+ T cells, rather
than CD8+ T cells, and its protective effects are likely exerted through macrophage
activation130,144,148. Despite its importance to parasite resistance, IFNg also produces deleterious
effects. Like macrophage-produced TNFa (described above), IFNg has been shown to inhibit T
cell proliferation during T. brucei infection140. Further, excessive IFNg production causes
systemic inflammation and early mortality in trypanosome infections; the pro-inflammatory
effects of this cytokine must be balanced by anti-inflammatory action of IL-10135,148.
1.8.4

T. brucei-mediated immunosuppression
Beyond antigenic variation, another way T. brucei evades host immunity is by

perturbation of the function of host immune factors. Two trypanosome-derived factors, TbKHC1
and TbAdC, have been shown to facilitate T. brucei infection by modulation of host innate
immune responses149,150. Another trypanosome-derived protein, TSIF, causes suppression of T
cell proliferation and anti-inflammatory IL-10 production, contributing to pathogenesis151.
Detrimental effects on B cell function and the maintenance of B cell populations have also been
observed at multiple stages of infection. Starting early in infection, non-specific, polyclonal B
cell activation and proliferation occurs (likely through B Cell TLR signaling initiated by
trypanosomal CpG DNA or the VSG GPI anchor), which may exhaust or suppress B cell ability
to generate antigen-specific antibodies152-155. As infection progresses, lymphopoiesis in the bone
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marrow is impaired, and transitional B cells (those developing from immature to mature B cells),
follicular B cells, and marginal zone B cells are depleted in the spleen via both polyclonal
activation and induction of apoptosis156-158. While the mechanisms behind these phenomena are
unclear, follicular B cell apoptosis has been demonstrated to be IFN-g dependent, and induction
of transitional B cell apoptosis appears to require direct trypanosome-B cell contact156. Finally, B
cell memory and protective antibody titers have been shown to be weakened or abolished several
weeks into T. brucei infection. At these later time points, mice re-challenged with parasites
expressing a VSG that they have previously established immunity against show impaired
secondary antibody responses and decreased control of the re-administered parasites159,160. Mice
vaccinated against B. pertussis also lose the protective effect of vaccination when challenged
with B. pertussis following T. brucei infection160. Collectively, these results suggest that B cell
depletion and exhaustion of the B cell repertoire contribute to the pathogenesis of T. brucei
infection by reducing the ability of the host to mount a humoral immune response against
successive waves of parasitemia, particularly at later stages of infection.
1.9
1.9.1

Open questions
VSG switching at the protein level
Most analyses of the antigenic variation process in T. brucei have focused on genetic

factors regulating VSG expression and diversification, but protein dynamics also influence the
host-pathogen interface and successful immune evasion. Following a genetic VSG switch,
trypanosomes must replace their entire VSG coat. During this period, trypanosomes
simultaneously express both pre- and post-switch VSGs on their surface, a phenomenon that has
been observed in infection isolates161. This coat replacement process is critical for the survival of
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recently switched cells because initial VSGs remain targets for the escalating host antibody
response, but the dynamics of VSG replacement remain poorly understood. VSG half-life
measurements suggest that initial VSGs may persist on the surface of genetically switched
trypanosomes for several days82,83. However, this estimate assumes that VSG turnover is identical
in recently switched and non-switched trypanosomes. It has been proposed that trypanosomes
might expedite VSG turnover during VSG switching as an immune evasion strategy162, but the
rate of VSG coat replacement has not been experimentally determined due to the low switching
frequencies observed in lab adapted trypanosome cell lines in vitro113,118,119,124 (discussed in
section 1.7.5). Furthermore, the vulnerability of trypanosomes with partially replaced coats to
antibody-mediated clearance has not been directly investigated. Thus, the specific mechanisms
that allow switched trypanosomes to successfully escape the mounting antibody response are yet
undetermined. In Chapter 2 of this thesis, I describe my examination of the dynamics of VSG
coat replacement and identification of a key factor influencing the susceptibility of cells
undergoing coat replacement to antibody-mediated clearance.
1.9.2

VSG structural diversity and VSG classes
Structural information and VSG sequence alignments have been used to allocate the

variable N-terminal domains of VSGs into three different classes (major classes A and B, and
minor class C) based on the presence of analogous cysteine residues123,163, and C-terminal
domains have also been grouped into six classes based on conserved sequence features114,123,163.
The two early N-terminal domain structures of VSG2 (also termed MITat1.2 and VSG221) and
ILTat1.24, and a more recently published structure (VSG M1.1, which is highly homologous to
VSG251) all belong to N-terminal class A. Sequence analyses of class B VSGs show that they
contain some similar features as the class A VSGs (such as long antiparallel α-helices)50, but it is
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unclear whether these VSGs also share the conserved structural motif which has been identified
in the VSG structures published to date. Because detailed VSG structural information is limited
to a handful of variants out of the thousands of known VSG genes, it is quite possible that VSGs
contain structural elements or confirmations that have not been identified. In Chapter 3 of this
thesis, I describe a collaborative body of work in which the crystal structure of a class B VSG
(VSG3, also termed MITat1.3 and VSG224) was solved, yielding unexpected findings regarding
the diversity of VSG post-translational modifications and the role of these modifications in hostparasite interactions.
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Chapter 2
VSG density defines an immune evasion threshold for African trypanosomes
undergoing antigenic variation
2.1

Introduction
Following a genetic VSG switch, trypanosomes must replace their VSG coat to evade

host antibodies that target the initial (pre-switch) VSG. Using published VSG half-life values82,83,
I calculated that full VSG coat replacement would take approximately 5.7 days. Because VSGspecific IgM antibodies can be detected as early as 4 days post infection40, this timeline
suggested that genetically switched trypanosomes would still display cognate initial VSGs on
their surface as the antibody response developed. I therefore reasoned that a detailed examination
of VSG coat replacement could improve our understanding of T. brucei infection dynamics, and
potentially reveal unidentified factors influencing parasite immune evasion. In this chapter, I
describe two experimental avenues by which I evaluated the coat replacement process. First, I
directly compared VSG turnover in recently switched and non-switched trypanosomes to
determine whether the parasites might expedite VSG turnover immediately post-switch as an
immune evasion strategy. Second, I performed in vivo infection experiments and in vitro
antibody binding analyses to examine the susceptibility of trypanosomes at intermediate stages
of coat replacement to IgM-mediated clearance.
2.2

Identification of switched populations undergoing VSG coat replacement by flow
cytometry
To examine the possibility that trypanosomes expedite VSG turnover following a VSG

switch, I first needed a method to identify switched trypanosomes soon after the change in VSG
expression occurred. Historically, it has been difficult to observe such cells because VSG
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switching occurs at a low frequency in vitro (10-5 - 10-6 cells per population doubling [C/PD])
113,118,119,124

. However, a transgenic cell line recently published by our group can be induced to

switch at a very high frequency43. The cell line (D70) has deleted 70 bp repeats (described in
sections 1.7.1-1.7.3) and an inserted I-SceI restriction site upstream of the active VSG (VSG2,
a.k.a. Lister 427-2, VSG221) (Fig. 2.1a), as well as a tet-inducible I-SceI gene in a spacer region
within the rDNA. Doxycycline (Dox) induction initiates an I-SceI-mediated double strand DNA
break (DSB) near the active VSG, the repair of which yields a high percentage of trypanosomes
(~10%) switching exactly once to another VSG43.
Because of its extremely high frequency of switching (the highest we have ever seen in
vitro), I reasoned that I could use the D70 cell line to visualize a large population of cells
undergoing VSG coat replacement via flow cytometry (Fig. 1). In these experiments, D70
cultures were induced with Dox for a 6-hour period, after which the cells were washed and
grown in Dox-free media. Samples were then taken at various time points for flow cytometry
analysis. Cells were stained with antibodies recognizing two different VSGs: VSG2, the initial
pre-switch VSG; and VSG3 (a.k.a. Lister 427-3, VSG224), one of many possible post-switch
VSGs. VSG3 was chosen because this cell line switches to that particular VSG more frequently
than others (~15% of the switched population expresses VSG3)43.
In accordance with the previously observed results, D70 cells did not switch at high
frequency in the absence of Dox, but Dox-induced cells switched at a rate of ~10-1 – 10-2 C/PD,
(Fig. 2.1b). By analyzing the emergence of cells staining positive for VSG3 at early time points,
I determined that switched cells could not be identified until ~12 h after the beginning of Dox
induction (i.e. ~6 h after the end of Dox induction). At 12 h, these VSG3+ cells also stained
highly positive for VSG2, indicating that they were simultaneously displaying both VSG2 and
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VSG3 as they underwent VSG coat replacement (Fig 2.1c). From 12 h – 48 h, the large
population of switched cells (both VSG3+ and VSG3-) could be seen decreasing in VSG2
staining level as the VSG2 was replaced with new VSG (Fig. 2.1c). Thus, all cells undergoing
coat replacement could be distinguished from non-switched cells by the level of VSG2 antibody
staining. Further, the rate of VSG coat replacement could be determined by the decrease in
fluorescence intensity over time. However, this method alone would not allow direct comparison
of the rate of VSG turnover in switching and non-switching cells. Non-switching cells still turn
over VSG2, but they continue to express VSG2, and therefore VSG2 antibody staining levels do
not change (Fig 2.1c, population in top left quadrants).
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Figure 2.1. Visualization of switching cells by flow cytometry.
(a) Diagrams of the active VSG expression sites (BES1) of WT cells and the Δ70 line (adapted
from43). WT diagram shows the promoter (bent arrow), ESAG1, the 70 bp repeats (rpts.), a VSG
pseudogene (ψ), the active VSG (VSG2), and the telomere (circle). In the Δ70 line, the 70 bp rpts.
and ψ are deleted and replaced with an I-SceI restriction site and a puromycin resistance gene
(PURO). (b) VSG switching in induced (Dox+) and non-induced (Dox-) Δ70 cells at 48hrs. (c)
Δ70 trypanosomes undergoing VSG coat replacement following a genetic VSG switch.
Percentage of cells in each quadrant are shown at 6 hr and 48 hr. For both (a) and (b), cells were
induced to switch at time t = 0 hr. VSG2 is the initial, pre-switch VSG, while VSG3 is one of
many possible post-switch VSGs.
2.3

Development of a specific, high efficiency VSG labeling method using the enzyme
Sortase A
To examine VSG turnover in switching cells as well as non-switched cells that maintain

consistent VSG2 levels, I developed a method of fluorescently labeling surface VSGs on live
trypanosomes. The goal was to label a pool of surface VSGs and calculate the rate of VSG
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turnover in both switching and non-switching cells by measuring the loss of fluorescence
intensity over time. The labeling method I designed was based on the transpeptidase enzyme
Sortase A, derived from Streptococcus pyogenes (hereafter referred to as only “sortase”). Sortase
recognizes the peptide “sorting motif” (LPXT[GG/AA]), cleaves the motif between the Thr and
[GG/AA] residues, and mediates a covalent bond between the Thr residue and an additional
peptide substrate containing an N-terminal (Gly)3 or (Ala)2 sequence in a process known as
“sortagging”164. Thus, if the VSG and a fluorophore-peptide conjugate each contained either the
sorting motif or N-terminal (Gly/Ala) residues in the correct combination, the sortase enzyme
would covalently attach the fluorophore to the VSG. As opposed to other potential VSG-labeling
strategies, sortagging would specifically label the VSG instead of other T. brucei proteins. It
would also be a highly versatile labeling technique, allowing attachment of not only fluorophores,
but also (theoretically) any molecule that could be conjugated to the proper peptide sequence.
To attempt to generate a recombinant “sortaggable” VSG2, I created several constructs
based on a previous study in which 11 sites were identified in VSG2 that were conducive to
peptide insertion165. I designed 3 peptide insertion sequences to introduce a sorting motif into the
identified sites in VSG2: (1) GGGLPETGGS, (2) LPETGGSGLEVLFQGPG (Prescission
Protease site underlined, included to make peptide more flexible by cleaving via protease
treatment), and (3) LPETGGSLPETGGSLPET (3 sorting motifs). I also designed an insertion
peptide (GGGENLYFQGGG; TEV protease site underlined) that would leave an N-terminal
(Gly)3 sequence in the VSG once treated with TEV protease (to serve as the N-terminal substrate
for a sortagging reaction together with a fluorophore-peptide containing a sorting motif). I
inserted these peptides into the 11 identified sites within the VSG2 gene, and cloned the
recombinant genes into a previously established vector, pUB39166, making 44 constructs in total.
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Based on the pUB39 backbone, the VSG2 genes in the resulting constructs were targeted for
insertion into the T. brucei rDNA spacer region and were preceded by a Tet operator, such that
the recombinant VSG2 proteins would be expressed under Dox/Tet control. Upon transfecting
these constructs into VSG3-expressing trypanosomes (from the “Single Marker” lineage167), only
some of the recombinant VSGs were successfully expressed on the cell surface following Dox
induction, as determined by flow cytometry using anti-VSG2 antibodies. Unfortunately, none of
the recombinant VSG2 proteins containing sorting motifs could be labeled following incubation
with purified sortase enzyme and the complementary fluorophore-peptide (see Methods for
sortase expression and purification and source of synthesized peptides).
I ultimately succeeded in creating a sortaggable VSG2 because of two key insights: (1)
the mature VSG2 naturally contains an (Ala)2 sequence at the N-terminus following cleavage of
an N-terminal signal peptide163, and this could serve as a substrate for the sortagging reaction;
and (2) this VSG2 N-terminus was likely inaccessible to sortase, because it is located too close to
the body of the protein50. I therefore reasoned that I might be able to render the (Ala)2 sequence
accessible by extending the VSG2 N-terminus. Fortuitously, one of the peptide insertion
constructs I had already designed contained such an extension. This construct (originally called
“VSG2-1D”) will henceforth be referred to as “VSG2STa”. The natural N-terminal sequence of
VSG2 is AAEKGFKQAF, while the N-terminus of VSG2STa is
AAGGGENLYFQGGGGGGFKQAF (peptide insertion underlined). A diagram of the
sortagging reaction with VSG2STa and a sorting motif-containing peptide conjugate is shown in
Fig. 2.2a. I first expressed the VSG2STa construct within a VSG3-expressing cell line (as
described above). I found that live cells expressing VSG2STa were successfully sortagged with
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fluorophore (FITC) when incubated with sortase and the peptide conjugate FITCGGGSLPETGG, whereas cells expressing only wild type VSG2 or VSG3 were not (Fig 2.2b).
a

b

VSG2

Molecule of choice
(e.g. fluorophore)
Sorting motif

C-Terminus

% of max

N-Terminus

VSG2STa

VSG coat

(

)n

Fluorescence intensity (FITC)

No reagents
Sortase only
FITC-peptide only
Sortase + FITC-peptide

+ Sortase

VSG2 coat with engineered
N-terminus (VSG2STa)

VSG3

Sortagged VSG coat

Figure 2.2. Sortagging live trypanosomes with engineered VSG2STa.
(a) Illustration of VSG2STa sortagging. (b) Flow cytometry analysis of live trypanosomes
following incubation with sortagging reagents. VSG2STa (expressed ectopically in a VSG3expressing cell line) is sortagged only when incubated with both sortase and a FITC-peptide
conjugate containing a sorting motif (FITC-GGGSLPETGG). Wild type VSG2- and VSG3expressing cells are not sortaggable. VSG image in (a) was adapted from a previous publication75
with permission from the author.
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Having engineered a sortaggable VSG, I next developed a construct to insert the VSG2STa
gene into the active BES (BES1) of the VSG2-expressing single marker (SM) cell line167,
replacing the wild type VSG2 gene (Fig. 2.3a). The construct, pSY37F1D-CTR, includes in
order: the VSG2 co-transposed region (CTR), which contains the 5’ VSG2 untranslated region
(UTR); the VSG2STa gene with its 3’ UTR; a Hygromycin resistance gene (HYG); and a
telomere-abutting sequence called the telomere seeds. Transfecting this construct into
trypanosomes introduces VSG2STa into BES1 via BIR through homology in the VSG2 CTR, after
which a new telomere grows from the telomere seeds. I transfected the construct into SM
parasites, resulting in the clone KI-VSG2STa (Fig. 2.3a). Proper insertion of the construct was
verified by southern blot (Fig. 2.3b), confirming that KI-VSG2STa exclusively expressed VSG2STa.
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(KI-VSG2STa)
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2STa
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8
6
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Figure 2.3. Creation of VSG2STa knock-in clone KI-VSG2STa.
(a) (Top) Diagram of the active BES (BES1) in VSG2-expressing single marker (SM) cells;
shows the promoter (bent arrow), a VSG pseudogene (ψ), 70 bp repeats, the VSG2 co-transposed
region (CTR), VSG2, the telomere seed region (TS) and the telomere (circle). (Middle) The
pSY37F1D-CTR construct containing VSG2STa and a hygromycin resistance gene (HYG) is
recombined into BES1 via break-induced replication (BIR) using the VSG2 CTR for homology.
(Bottom) Diagram of resulting BES1 in the VSG2STa knock-in clone KI-VSG2STa. (b) Southern
blot of genomic DNA (gDNA) from SM and KI-VSG2STa cells digested with SmaI and probed
against VSG2. KI-VSG2STa gDNA contains the appropriate 8.3 kb band as shown in (a).
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I then used the KI-VSG2STa clone in a series of experiments to test and optimize the VSG
sortagging platform (Fig 4). I found that VSG sortagging was a versatile tool, as I was able to
label cells with diverse “tag” molecules conjugated to or containing the peptide sorting motif.
These tags included fluorophores (e.g. FITC), the small molecule hapten nitrophenol (NP), and
GFP (with GGGSLPETGG added to the C-terminus) (Fig 2.4a). Secondly, I found that while
the literature describes the “universal” sorting motif as LPXTG168,169, the sortase enzyme I used
(derived from S. pyogenes) functioned at greatest efficiency when the sorting motif was LPSTG
(Fig. 2.4b), and I therefore used this motif for all subsequent sortagging. Unsurprisingly, LPSTG
is also the motif typically used by the S. pyogenes bacteria170.

NP

GFP

b

% of max

FITC

% of max

a

Fluorescence intensity

Media only

Sortase + Tag

Fluorescence intensity (FITC)

Media only
E

G
S

Figure 2.4. Sortagging versatility and sorting motif optimization.
(a) Sortagging live KI-VSG2STa cells with different tags: FITC (FITC-GGGSLPSTGG),
nitrophenol (NP) (NP-GGGSLPSTGG), and GFP (GFP-GGGSLPETGG). Cells were incubated
in HMI-9 media with or without sortase and tag. NP-tagging of trypanosomes was visualized
after staining with fluorophore-conjugated anti-NP antibody (b) Testing multiple sorting LPXTG
motifs (tags are FITC conjugated to GGGSLPXTGG where X is E, G, or S as indicated).
“Media only" represents cells incubated in HMI-9 without sortase or tag.
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Finally, I performed additional control experiments to verify that VSG sortagging would
be a viable method of measuring VSG turnover. First, to examine whether sortagging affected
trypanosome growth rate, I developed a protocol to stain trypanosomes with CFSE (an
intracellular fluorescent stain that dilutes as a result of cell proliferation, and is commonly used
as a proliferation metric171). I compared the growth rates of tagged and non-tagged trypanosomes
by measuring the decrease in CFSE mean fluorescence intensity (MFI) in each population over
time, and found that sortagging had no effect on proliferation (Fig 2.5a). Second, fluorescence
microscopy of trypanosomes 12 hours after sortagging showed that sortagged VSG was still
evenly distributed across the cell surface (Fig. 2.5b). This even distribution suggests that
sortagged VSGs are trafficked as normal VSGs and are not grouped or sequestered while on the
cell surface, during cell division, or during VSG endocytosis and recycling. Finally, decrease in
the fluorescence intensity of sortagged trypanosome populations cultured over time indicated
turnover of these labeled VSGs (Fig. 2.5c). However, in order to use fluorescence intensity as an
accurate metric of VSG turnover, I still needed to account for non-linearity in raw MFI
measurements. To do this, I used a set of commercial calibration beads to convert the MFI of
each trypanosome sample into Molecules of Equivalent Soluble Fluorochrome (MESF) units172
(described in Methods). MESF units represent the mean absolute fluorophore amount per cell,
and therefore the mean absolute number of tagged VSGs per cell (Fig. 2.5c).
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Figure 2.5. Validation of fluorescent sortagging as VSG turnover measurement strategy.
(a) Lack of effect of sortagging on cell growth rate. Data show flow cytometry measurements of
population mean fluorescence intensity (MFI) of CFSE. Cells were treated with HMI-9 alone
(Media only), or HMI-9 with sortase enzyme, fluorescent tag, or both sortase and tag; then with
CFSE prior to culture. (b) Live KI-VSG2STa trypanosomes 12 hours after sortagging with the
fluorophore FITC. (c) Loss of FITC-sortagged VSGs over time in KI-VSG2STa trypanosomes.
Population mean fluorescence intensity (MFI) values were converted to absolute units
(Molecules of Equivalent Soluble Fluorochrome, MESF)172. Sortag MESF (plotted on left Y
axis) is the mean amount of sortagged VSG remaining per cell. Dotted line is associated with the
left Y axis and represents background MESF of non-sortagged cells. Sortag MESF x total cells
(plotted on right Y axis) is the total cell-associated, sortagged VSG remaining in the population.
This value was calculated by subtracting background MESF from the sortag MESF value and
multiplying by the total number of cells in the population
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2.4

Calculation of VSG turnover rates in switching and non-switching cells
I then inserted the sortaggable VSG2STa into the VSG expression site of the high switching

D70 cell line, replacing the active VSG2 gene (D70STa). This allowed me to calculate the rate of
VSG loss in both switched and non-switched cells by quantifying decreases in fluorescence
intensity from antibody staining and sortagging over time (Fig. 2.6a-c). Because flow cytometry
measures individual cells, VSG loss rates were calculated at the single-cell level, and therefore
include contributions both from the dilution of VSGs during cell division (population doubling
time, tD) and from VSG shedding and degradation (VSG half-life, t1/2). Evidence of the latter
factor, (loss of VSGs from the entire trypanosome population by shedding and degradation) is
shown by the negative slope of the “Sortag MESF x total cells” curve in Fig. 2.5c above. The
combined VSG loss rate at the single-cell level is the rate most relevant to immune evasion, and I
have termed this value the “effective VSG half-life” (tE1/2). Calculated tE1/2 values (~4.6 hrs on
average, Fig. 2.6c) agreed between measurement methods, and were similar to previously
published population-wide data (~5.9 hrs, see section 2.4.1 for calculation)82,83. Notably, tE1/2
values were comparable for switched and non-switched cell populations, indicating that VSG
turnover rates are identical in recently switched and non-switched cells. These results were not
confounded by large differences in growth rate between cell populations (Fig. 2.6d). Based on
this tE1/2 of 4.6 hrs, trypanosomes with fully replaced VSG coats would not arise until
approximately 107 hrs (~4.5 days) after a genetic VSG switch (See section 2.4.1 for calculation),
suggesting that switched trypanosomes and their progeny may be susceptible to immune
clearance for extended periods.
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Figure 2.6. Calculation of VSG turnover rates in switching and non-switching cells.
(a) VSG2STa loss over time in sortagged and induced (+Dox) or non-induced (-Dox) Δ70STa cells.
Line shows the gate between “Switcher” and “Non-switcher” populations. (b) and (c)
Calculation of rates of VSG loss (tE1/2) in Switcher and Non-switcher populations as gated in (a).
For (d), Raw MFI values for Ab staining and sortag levels were converted to MESF units (see
Methods). Lines on plots show non-linear regression analyses. (e) tE1/2 calculated for indicated
populations (Value ± SE) and goodness of non-linear regression fit (R2). (d) Relative growth
rates of Switcher and Non-switcher populations measured by CFSE staining.
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2.4.1

Details of VSG turnover rate calculations
The estimated expected tE1/2 value from previously published data can be calculated via

the equation in Fig. 2.7a. Using the D70STa clone tD (7.2 hrs, Fig 2.7b) and published t1/2 of 32
hrs82,83, the expected tE1/2 value is ~5.9 hrs. The total duration of the VSG coat replacement
process can be calculated via the equation in Fig. 2.7c. Using the values N0 = 107 VSGs (a full
coat prior to genetic VSG switch), and tE1/2 = 4.6 hr (Fig. 2.6c), the estimated time to reach N = 1
VSG remaining is 107 hrs (~4.5 days). Beyond this point, trypanosomes with fully switched
coats will arise.
a
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1
1
1
=
+
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Figure 2.7. VSG turnover equations and D70STa growth rate.
(a) Equation relating tE1/2, tD, and t1/2 (tE1/2 = VSG effective half-life. tD = trypanosome population
doubling time. t1/2 = VSG protein half life). Both VSG dilution through cell division and VSG
loss through shedding and degradation contribute to the total rate of VSG loss from each
individual trypanosome. The combined half-life value (tE1/2) is mathematically equivalent to the
sum of the inverses of these partial half-life values. (b) Growth rate of D70STa. (c) Formula to
calculate initial VSG remaining over time during coat replacement. N0 = total initial VSG at time
t = 0 (i.e. ~107 VSGs, or 100%). t = time since genetic VSG switch occurred. N = amount of
initial VSG remaining after time t. These equations were adapted83 for ease of interpretation in
the context of this thesis.
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2.5

Generation of dual expressor (DE) trypanosomes that co-express two VSGs at varied
ratios
To understand the impact of VSG coat replacement dynamics on successful immune

evasion during an infection, I sought to examine the vulnerability of trypanosomes with partially
replaced coats to antibody-mediated clearance. I first needed to generate a set of dual-expressor
(DE) trypanosome clones that simultaneously expressed two surface VSGs at varied ratios,
representing switched cells at intermediate stages of coat replacement. The mechanisms that
control gene expression levels in T. brucei are poorly characterized. However, studies have
shown that alterations in the 5’ and 3’ UTR sequences flanking genes can affect mRNA and
protein expression levels173,174. With this in mind, I designed a strategy to create a set of DE
clones using varied UTR sequences to modulate VSG expression.
I developed a set of constructs to modify a parental cell line originally expressing VSG3
(WT-VSG3) by inserting VSG2 into the VSG3 expression site upstream of VSG3 (Fig. 2.8a),
following a strategy similar to that demonstrated in previous publications175. In this design,
VSG2 and VSG3 represent pre-and post-switch VSGs, respectively. My constructs each
contained a blasticidin (BSD) resistance gene and a VSG2 gene flanked by a unique set of UTRs,
and this entire cassette was targeted to a unique region in BES1 by flanking homologies (Fig.
2.8a). Lacking an obvious empirical reason to choose any particular UTRs, I experimented with
combinations of UTRs from (1) VSG2 itself, (2) T. brucei genes that are commonly used in lab
vectors (actin, aldolase), and (3) a modified procyclin 5’ UTR used in the study173 that
demonstrated 5’ UTR-mediated modulation of gene expression. This strategy was successful in
generating DE clones with varied VSG2 surface expression levels (Fig. 2.8b). VSG2 expression
levels were stable over time in each clone (Fig. 2.8c), and reproducible between clones
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transfected with the same construct. Previous studies have shown that co-expression of two
VSGs does not perturb trypanosome growth or normal cellular function175,176, and I also observed
no growth defect in the DE clones (Fig. 2.8d). To ensure that my calculations of surface VSG2
expression ratios (Fig. 2.8b) were accurate, I performed the flow cytometry-based measurements
underlying these data using a saturating concentration of anti-VSG2 antibody (Fig. 2.9a). Similar
measurements of VSG3 expression levels in the DE clones indicated that VSG2 expression did
not affect the amount of VSG3 present on the cell surface (Fig. 2.9b and c).
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Figure 2.8. Dual-expressor clones stably express two VSGs at different ratios.
(a) Construction of dual-expressor (DE) clones. (Top) Diagram of the active VSG
expression site (BES1) of the parental cell line shows the promoter (bent arrow), 70 bp repeats
(rpts.), a VSG pseudogene (ψ), the telomere (circle), the active VSG (VSG3), and an intergenic
region unique to BES1 (orange). (Bottom) The VSG2 insertion constructs contain a Blasticidin
resistance cassette (BSD) and a VSG2 gene flanked by 5’ and 3’ UTRs that are unique to each
construct. These insertions are targeted to BES1 by homology to the indicated intergenic region.
(b) Analysis of the level of surface VSG2 present on DE clones. Raw fluorescence intensity
values (population MFI via VSG2 Ab staining at saturating concentration, see Fig. 2.9a) were
converted to absolute units (MESF). VSG2 level was calculated as a percentage of the MESF
value of a full VSG2 coat (WT-VSG2). Table indicates 5’ and 3’ UTRs used and the resulting
percentage of surface VSG2 expressed for each clone. Bars and % VSG2 values represent mean
± SD. (c) Stability of surface VSG2 levels expressed by DE clones (population MFI, VSG2 Ab
staining) in culture. (d) Growth rate analysis of WT-VSG2, WT-VSG3, and DE clones.
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Figure 2.9. Flow cytometry-based measurements of VSG surface expression.
(a) Titration curve of monoclonal anti-VSG2-Alexa647 Ab staining of WT-VSG2 cells. Data are
represented as population mean fluorescence intensity (MFI) measured via flow cytometry (see
Methods for sample preparation). Saturating levels of VSG2 staining were reached with this Ab;
arrow indicates the concentration used for calculation of relative surface VSG2 expression in DE
clones (Fig. 2.8b). (b) Titration curve (as in (a)) of monoclonal anti-VSG3-FITC Ab staining of
WT-VSG3 cells. After several fluorophore conjugation and Ab concentration attempts, I was
unable to obtain a saturating concentration of this Ab. (c) Analysis of anti-VSG3-FITC staining
at non-saturating levels (at concentration indicated by arrow in (b)), indicated that the amounts of
surface VSG3 expressed by WT-VSG3 cells and each of the DE clones are approximately equal.
Unlike the VSG2 ratio measurements (Fig. 2.8b), this result should be valid even without
saturating conditions, as cells with equal VSG3 staining will not differentially affect the free
anti-VSG3 Ab concentration present during staining.
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2.6

Development of an immunization strategy to elicit a VSG-specific IgM response
During infection, T-cell independent VSG-specific IgM responses comprise the most

rapid host defense against parasite proliferation132, and non-switched trypanosomes have been
shown to be cleared predominately via early arising IgM antibodies40 (see section 1.8.1 for
further discussion). Therefore, my goal was to develop a mouse immunization strategy to elicit
VSG-specific IgM in order to best replicate the natural immune environment of cells undergoing
VSG coat replacement. Using this strategy, I could raise IgM against VSG2 in mice, and then
challenge the mice with the DE clones to determine each clone’s susceptibility to VSG2-specific
IgM-mediated clearance. To examine the kinetics of the antibody response to T. brucei infection,
I infected mice with an injection of 50 SM (VSG2-expressing) trypanosomes, cleared the
infection on day 4 using the drug berenil, and took blood samples on days 4-14 to monitor the
development of the antibody response by ELISA. In agreement with previously published
data40,157, anti-VSG IgM reached peak titers on days 8–10 post-infection (Fig 2.10a). Classswitched IgG antibodies did not arise in most mice until day 12 or later, although IgG was
detectable in the serum of one mouse on day 10. These IgM dynamics meant that common
strategy of infecting mice with live trypanosomes and clearing with drugs prior to re-challenge
was not suitable for my experiments. Berenil, the drug used to clear infection, produces a
prophylactic effect lasting as long as 28 days177, leaving the mice protected against challenge
with parasites expressing any VSG well beyond the timeline of the early IgM response.
To solve this problem, I tested multiple strategies to prepare killed, non-infectious
trypanosomes that could be used for immunization. Formalin fixation was an option, but studies
have shown that very large quantities of fixed trypanosomes are needed to generate a strong
immune response132, and fixation would likely disrupt the protein coat. As alternative options, I
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decided to try heat killing and UV-irradiation. Dead trypanosomes normally release their surface
VSG due to an endogenouse lipase (GPI-PLC, see section 1.6), rendering them unusable for
elicitation of VSG-specific responses. I therefore used a VSG2-expressing cell line that lacks
GPI-PLC and retains an intact VSG coat following cell death85. Numerous attempts at heat
killing resulted in trypanosome samples that were either denatured by overheating, or not fully
killed (live trypanosomes would appear over time when the samples were cultured). In contrast, I
was able to design a UV-irradiation protocol that reproducibly fully deactivated trypanosome
samples while leaving the VSG coats intact. I then compared these immunizations using UVirradiated trypanosomes to injection and clearance of live trypanosomes. For the UV-irradiated
immunizations, I tried single injections (day 0 only), as well as double (days 0 and 3) and triple
(days 0, 2, and 4) injections. Multiple injections were better than a single injection, but triple
injections did not improve the IgM response over double injections (Figure 2.10b). Double
injections of UV-irradiated trypanosomes elicited a VSG2-specific IgM response approximating
that elicited by live trypanosomes, and significant production of class-switched (IgG) antibodies
was not observed during the 14 days following immunization (Fig. 2.10c). The double UVirradiated trypanosome injection strategy thus appeared to meet the requirements of generating a
strong IgM response while not infecting the mice or introducing prophylactic drug treatment.
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Figure 2.10. Dynamics of antibody response to live and UV-irradiated trypanosomes
VSG2-specific IgM and IgG titers elicited by live or UV-irradiated trypanosomes. Data show
relative titers over time (days after initial injection) as measured by ELISA. (a) 50 VSG2expressing (SM) trypanosomes were injected into mice (M1-5) on day 0 and cleared with berenil
on day 4. (b) Mice received an injection of 3 x 106 UV-irradiated trypanosomes on each of the
days indicated. ELISA data of mouse serum collected prior to immunization is labeled “Preimm.” (c) Live or UV-irradiated trypanosomes were injected as indicated. Live trypanosomes
were cleared with berenil on days 4 or 5. ELISA data of mouse serum collected prior to
immunization is labeled “Pre-imm.” For (a) and (c), error bars represent mean ± SD (n = 3
mice/group), and dotted lines indicate average background OD in wells incubated with no serum.
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2.7

Only partial coat replacement is required for immune evasion
I then used the immunization protocol to assess whether my DE clones could evade a

VSG2-specific IgM response in vivo (Fig. 2.11). Immunized and non-immunized control mice
received challenge injections at day 8 post-immunization, at which point the immunized mice
had high IgM titers, and low or undetectable IgG titers (Fig. 2.11a). Challenge injections
contained 100 live WT-VSG2 (expressing VSG2 only), WT-VSG3 (expressing VSG3 only),
DE-1.3, DE-7.6, or DE-11 trypanosomes. Starting at day 4 post-challenge, mice were monitored
for survival, and blood smears were examined daily for the presence of trypanosomes. My results
clearly demonstrated a threshold surface VSG2 level required for IgM-mediated trypanosome
clearance. Clones with surface VSG2 levels ≥7.6% (DE-7.6, DE-11, and WT-VSG2) were either
cleared entirely or exhibited delayed infection in immunized mice (Fig. 2.11b), and VSG2 levels
≥7.6% also correlated with a survival advantage for immunized mice (Fig. 2.11c). In contrast,
WT-VSG3 and DE-1.3 clones were not affected by pre-immunization in terms of infection
dynamics (Fig. 2.11b), survival of infected mice (Fig 2.11c), or parasitemia levels during the first
peak of infection (Fig. 2.11d). The lack of evident pressure from VSG2-specific antibodies on
DE-1.3 trypanosomes was striking, as VSG2 proteins are abundant on the surface of these cells
(~1.3 x 105 VSG2 proteins/cell). These data suggest that switched trypanosomes escape the early
IgM response once they have replaced only ~99% of their initial coat.
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Figure 2.11. Immunization-challenge experiments with DE clones reveal a threshold of
immune evasion.
(a) VSG2-specific IgM and IgG Ab titers in the immunized and non-immunized mice (n = 49
mice/group) used for experiments shown in (b) and (c) at day 8 post-immunization (combined
results of three independent experiments). Data show relative titers as measured by ELISA.
Dotted lines indicate average background OD in wells incubated with no serum. (b) and (c),
Non-immunized mice and mice immunized against VSG2 were challenged with the trypanosome
clones indicated. (b) Percentage of mice with confirmed infection over time, and (c) survival
curves for immunization-challenge experiments. X axes indicate day post-challenge. Grey
shading indicates the period following clearance of the parasitemia peak resulting from
outgrowth of input parasites. For (b) mice were permanently scored as infected when
trypanosomes were first identified via blood smear. For (b) and (c), statistical analysis was
performed using the log-rank (Mantel-Cox) test (n = 9 for DE-7.6 immunized and DE-11 nonimmunized, 10 for other groups); *** P < 0.001, ** 0.001 < P < 0.01, N.S., not significant (P >
0.05). Data include combined results of three independent experiments (with n = 4 or 5 mice per
experimental group per experiment). One trypanosome clone of each type was used in these
experiments. (d) Levels of parasitemia at day 5 post-challenge in immunized and nonimmunized mice (mean ± SD, n = 5 mice/group). Immunized and non-immunized parasitemia
levels are not significantly different (P > 0.5) in mice showing parasitemia with WT-224 and
DE-1.3 clones, as determined by t-test (variances are similar between groups, as determined by
F-test). These data were collected in one experiment. (e) Lack of VSG2 and VSG3 expression in
late-arising (beyond day 8) DE-7.6 and DE-11 infections in pre-immunized mice. Data show
flow cytometry analysis of trypanosomes isolated from the blood of infected mice on day 15
post-challenge, along with control VSG2 and VSG3-expressing trypanosomes (WT-VSG2 and
WT-VSG3, respectively). The data shown are representative of late-infection trypanosome
isolates from all DE-7.6 and DE-11 infections observed in pre-immunized mice (1 infection in
DE-7.6 mice, 6 infections in DE-11 mice; one mouse from each group did not present
parasitemia high enough for trypanosome isolation and analysis).
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A more detailed analysis of these results requires separation of the infections into two
stages. Data from the first ~7 days post-challenge (Fig. 2.11b and c, unshaded regions) permits
the most straightforward interpretation. The parasitemia peak representing immediate outgrowth
of the input trypanosomes was uniformly detectable by day 4 or 5 post-challenge in nonimmunized mice. Suppression of parasitemia in immunized mice at this time must be interpreted
as a direct effect of pre-immunization on the survival of the input trypanosomes (Fig. 2.11b),
which was the interaction I intended to examine. After this initial period, however, host-parasite
interactions become more complex. If the input trypanosome peak occurred, mice either
succumbed to infection immediately, or cleared the peak on days 6-8 by generating antibodies in
response to the challenge injection. Mortalities occurring after day 8 thus resulted from
expansion of switched parasite populations expressing VSGs not present in the input injections.
Notably, trypanosomes isolated from several immunized mice that showed delayed infection
with DE-7.6 and DE-11 clones had indeed lost expression of both VSG2 and VSG3 (Fig. 2.11e),
suggesting that pre-immunization suppressed outgrowth of the input trypanosomes, but switched
populations emerged following some level of early infection that had been undetectable by blood
smear. Bearing these later complications in mind, the significant suppressive effects of preimmunization on clones with surface VSG2 levels ≥7.6% are still most readily explained by the
interactions of early IgM with the input trypanosomes during the first week of infection. Late
interactions between maturing immune responses elicited against the input VSGs and emerging
switched parasite populations may have some effect on the overall infection dynamics, but are
unlikely to be the predominant factors influencing these data.
Combining these results with the VSG turnover rate measurements presented earlier
permits a more complete analysis of the effect of coat replacement dynamics on successful
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immune evasion. Full coat replacement takes ~4.5 days, but switched cells reach 7.6% and 1.3%
initial VSG (levels on either side of the immune evasion threshold) after only 17.1 and 28.8 hrs,
respectively (calculations performed as described in section 2.4.1). These data therefore suggest
that although switched cells present initial VSG on their surface for extended periods, they are
only vulnerable to immune clearance for a small fraction of that time.
2.8

IgM binding ability is dependent on VSG density
To examine the mechanism(s) underlying this immune evasion threshold, I assessed the

ability of IgM to bind to the DE clones (Fig. 2.12). I raised VSG2-specific polyclonal IgM
antibodies in two mice. Both IgM samples strongly stained DE-7.6, DE-11, and WT-VSG2 cells,
but showed extremely weak or no binding to DE-1.3 and WT-VSG3 cells (Fig. 2.12a). To
interpret this binding behavior, I developed a model predicting the number of contacts an
individual IgM could make with surface VSGs present at varying densities. IgM is a pentameric,
decavalent molecule whose binding capability is generally based on low-affinity, high-avidity
interactions178. IgM is ~30-40 nm in diameter179,180, while the VSG coat has been modeled as a
hexagonal array of VSG homodimers with a spacing of ~5.8 nm181 (Fig. 2.12b). Using these
parameters, I predicted the number of initial VSGs within reach of a 40 nm-wide IgM at the coat
replacement stages represented by the DE clones (Fig. 2.12c, calculations detailed in Methods). I
estimate that a single IgM molecule can reach multiple initial VSGs at any given moment when
initial VSG composes ≥7.6% of the total surface VSG, but this is no longer true when that value
reaches 1.3%. I reached the same conclusion when I modeled this interaction assuming an IgM
diameter of 30 nm. Thus, my model suggests that the observed in vivo immune evasion and in
vitro IgM binding thresholds are driven by IgM’s fundamental requirement for multiple antigen
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contacts to allow successful binding and performance of effector functions. I therefore conclude
that antigenic density, not abundance, is a key determinant of the efficacy of early IgM responses.
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Figure 2.12. The effect of VSG density on IgM binding ability.
(a) VSG2-specific Ab binding to wild-type (WT) and dual expressor (DE) clones. Monoclonal
anti-VSG2 IgG Ab was used as a control to demonstrate the presence of surface VSG2 in all DE
clones (left). Binding ability of two polyclonal IgM antisera is shown on the right. Data are
representative of three replications of this experiment. (b) and (c) A model detailing a proposed
mechanism for the observed IgM binding threshold. (b) The binding footprint of IgM. Modeling
the VSG coat (bottom) as a hexagonal array of VSG homodimers with a spacing of ~5.8 nm, an
IgM molecule (top) with a diameter of 40 nm could contact a maximum of 61 homodimers (122
VSGs) at a single time. (c) The average number of initial VSGs within a given IgM binding
footprint at varying stages of coat replacement.
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2.9
2.9.1

Discussion
VSG coat fluidity affects IgM-VSG interactions
My mathematical model of the IgM-VSG coat interface (Fig. 2.12b and c) provides a

framework for evaluating the impact of VSG density on IgM-VSG binding based on the twodimensional scale of these interactions, but the dynamic nature of the system must also be
considered. The VSG coat is highly fluid, and each monovalent IgM-VSG interaction has some
discrete duration determined by the IgM’s binding kinetics. Thus, the ability of a single IgM to
make contacts with multiple cognate VSGs is actually based on the likelihood of a second
cognate VSG coming into range of a given IgM during an initial monovalent interaction. This
likelihood is highly influenced, but not fully determined, by average VSG spacing. Further,
hydrodynamic flow generated by beating of the trypanosomal flagellum has been demonstrated
to push surface VSG-Ig complexes towards the posterior end of the cell75, which could produce a
gradient of increasing VSG density on the trypanosome surface in vivo. This process may
thereby increase the likelihood of polyvalent IgM-VSG interactions, and consequently decrease
the expected threshold amount of cognate VSG necessary for IgM binding to a lower level than
my model predicts. Conversely, the shear forces that hydrodynamic flow applies to IgM-VSG
interactions could decrease the duration of each monovalent interaction, producing the opposite
effect on the expected threshold amount. Overall, in cases where trypanosomes have ≥7.6%
initial VSG remaining, a single IgM is likely to encounter multiple initial VSGs regardless of
whether the VSG coat is in motion. For lower VSG percentages, the expected effect is more
uncertain, though the empirical evidence presented here (Fig. 2.12a) suggests that the DE-1.3
clone is indeed below the IgM binding threshold. A deeper mechanistic evaluation would require
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performing a similar analysis of IgM binding to trypanosomes in whole blood under flow
conditions, but the technical capability to perform such experiments does not exist, at present.
2.9.2

The effect of VSG coat replacement on stimulation of a subsequent immune response
A prior study by Dubois et al.182 examined the phenomenon of VSG coat replacement

from another angle, demonstrating that trypanosomes simultaneously expressing two VSGs elicit
a weaker antibody response than trypanosomes expressing only one VSG. This result informs the
effect of VSG coat replacement on the development of new antibodies targeting subsequent
waves of parasitemia, but does not address my focus, the effect of the previously stimulated
antibody response on the switched (and partially coat-replaced) trypanosomes themselves. I did
not examine the antibody response elicited by the DE clones in detail, as it was beyond the scope
of this study. However, I do not see any conflict between my results and the results detailed in
this prior publication, and suggest that these studies should be viewed as related but distinct
bodies of work.
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Chapter 3
An O-linked VSG glycan influences parasite virulence and interactions with host antibodies
3.1

Introduction and background data
This chapter details a collaborative body of work characterizing structural, biochemical,

and functional attributes of VSG3 (a.k.a, Lister 427-3, MITat 1.3, VSG224). As a background to
my contributions, this introductory section contains a summary of three data sets generated by
collaborators: (1) the solving of the VSG3 crystal structure and the identification within the
structure of an O-linked glycan (subsection 3.1.1) in the laboratory of Dr. Erec Stebbins (current
address the German Cancer Research Center (DKFZ); Heidelberg, Germany); (2) mass
spectrometry analyses of the VSG3 O-linked glycan (subsection 3.1.2) performed in the
laboratory of Dr. Michael Ferguson (University of Dundee; Dundee, UK); and (3) identification
of analogous glycans in other VSGs (subsection 3.1.3) via analyses from both collaborators. I
was not involved in producing these data, and the associated techniques will not be included in
the Methods section of this thesis. These presently unpublished results are included here because
they form the basis of my contributions (and those of other Papavasiliou lab members) in
evaluating the influence of the VSG3 O-glycan on parasite virulence and evasion of the host
antibody response (described in the following sections of this chapter). Section 3.7 at the end of
the chapter lists the specific contributions of each researcher involved in this study.
3.1.1

Identification of an O-linked glycan on the membrane-distal surface of VSG3
The diverse VSGs of T. brucei have been categorized into three distinct N-terminal

classes (major classes A and B, and minor class C) based on patterns of analogous cysteine
residues123,163. Although there are thousands of known VSG genes, only three crystal structures of
VSG N-termini have been published to date, all belonging to class A50-52. Because of this lack of
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depth and diversity in sampling, it seemed plausible that the published structures were an
incomplete representation of the real structural variation between VSGs. Intriguingly,
preliminary examinations of a common class B variant, VSG3, showed that it scored poorly
against the class A VSG structures in structure-based prediction algorithms such as protein
“threading”183 (whereas the class A VSGs scored highly against one another). To examine
whether VSG3 might contain unidentified conformational variability, our collaborators
crystallized and solved the structure of this variant.
The VSG3 crystal structure did reveal several divergent structural features, but this thesis
will focus on the most unexpected discovery: the identification of an O-linked α-glucose moiety
attached to VSG3 residue S317 (Fig. 3.1). This O-glycan is located on the top (membrane-distal)
surface of VSG3, and is therefore likely to be highly exposed to the immune system.

a

b

O-Glc

O-Glc

N-Glc
S317
Figure 3.1. VSG3 structure reveals an O-linked glycan at residue S317.
(a) Structural diagram of VSG3. On the top surface of the upper lobe is a red space-filling
representation of the a-glucose moiety attached to residue S317 (O-Glc). An N-linked glycan
(N-Glc) is shown in the bottom lobe. A 90-degree rotation of the left model is rendered with
molecular surfaces. (b) 1.4 angstrom resolution electron density map from the refined model of
VSG3 clipped to the volume around the modeled glucose. S317 is shown connected to a ribbon
diagram representation of the protein main chain.
54

3.1.2

Heterogeneity in VSG3 O-glycosylation
Mass spectrometric analysis of intact VSG3 by ES-MS before and after digestion with

PNGaseF (which specifically removes N-glycans) validated the O-linked α-glucose moiety
identified in the crystal structure, and additionally revealed heterogeneity in the number of Olinked glycans present (Fig. 3.2a and b). Subsequently, peptide mass analysis by LC-MS/MS
confirmed that the peptide A311-K339 contained 0, 1, 2 or 3 hexose residues (Fig. 3.2c).

a

b

c

Figure 3.2. Mass spectrometry analysis reveals heterogeneity in VSG3 O-glycosylation.
Deconvolved electrospray mass spectra of purified native VSG3 N-terminal domain before (a)
and after (b) de-N-glycosylation with PNGaseF. The mass differences of ~162 Da between
VSG3 species indicate O-glycosyl heterogeneity. The lowest mass in (b), 38993.7 Da, agrees
with the theoretical mass for residues A20-G388 of VSG3 allowing for the conversion of N67 to
D67 by PNGaseF and four disulfide bonds (c) Extracted ion chromatogram showing the elution
profiles of [M+3H]3+ ions (m/z 1035.1, 1089.1, 1143.1 and 1197.1) for the A311 to K339 peptide
of VSG3 containing 0, 1, 2 and 3 hexose residues, respectively. These elute by reversed-phase
HPLC from most to least hydrophilic with decreasing numbers of sugar residues attached.
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The MS/MS product ion spectra of several peptide glycoforms further defined the Oglycosylation site as S317 (Fig. 3.3).

a

b

c

Figure 3.3. MS/MS characterization of heterogeneous O-linked VSG3 surface glycans.
The product ion mass spectra of [M+3H]3+ ions corresponding to the VSG3 peptide A311-K339
containing (a) zero, (b) one, and (c) two hexose residues. For (b), the diagnostic b7-Hex ion at
m/z 617.3 suggests that S7 in the peptide was converted to dehydro-alanine through belimination, defining the O-glycosylation site in the original VSG3 sequence as S317. For (c),
the b7 and b8 ions suggest that both hexoses are attached to S7 (S317 in the full VSG3 sequence)
and not to any other hydroxyl-amino acids in the sequence.
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Together, these data strongly indicate that there is a heterogeneous chain of 0-3 hexoses
attached to VSG3 residue S317. No evidence of additional glycosylation of serines or threonines
was observed. Based on the ES-MS spectra (Fig. 3.2a and b), the proportions of the 0, 1, 2 and 3
hexose glycoforms were estimated at 8%, 33%, 37%, and 22%, respectively. While O-linked
carbohydrates are known in other kinetoplastids184, such modifications have not been previously
described in T. brucei. Further, no carbohydrates of any kind have been previously been
identified on the top surface of a VSG.
3.1.3

Analogous O-glycans in other VSGs
The O-glycan in VSG3 is located in an exposed loop stabilized in the upper lobe by

flanking cysteines involved in a disulfide bridge (the peptide CTGSASEGLC, residues 314-323,
Fig. 3.4a). To assess the prevalence of surface O-linked glycosylation, our structural biologist
collaborator compiled a list of VSGs from diverse genomic locations34 with N-terminal domains
that threaded to VSG3 and contained cysteine-flanked, serine- or threonine-containing loops
analogous to the glycosylated loop in VSG3. A subset of this list is shown in Fig 3.4b. Two of
these (VSG11 and VSG615) and an additional VSG that did not thread to VSG3 (VSG21) were
analyzed by mass spectrometry. The results showed that both VSG11 and VSG615 possessed
heterogeneous O-linked hexose modifications analogous to those found in VSG3 (Fig. 3.4c and
d), while VSG21 did not. These data suggest that surface O-linked glycosylation could be a
widespread VSG modification present throughout trypanosome infections.
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a

c

b

d

Figure 3.4. Identification of heterogeneous O-linked glycans in additional VSGs.
(a) Cysteine-flanked glycan loop of VSG3 with the loop in yellow and the disulfide-bridged
cysteines shown as yellow spheres and labeled, S317 shown as a stick model in orange, and the
glucose atoms in red. (b) Comparison of hypothesized “O-linked glycan” loops in additional
VSGs. O-glycosylation was examined and confirmed for three VSGs (boxed in red): VSG3,
VSG11, and VSG615. (c) and (d) Extracted ion chromatograms showing glycan heterogeneity in
the elution profiles of [M+3H]3+ ions for the indicated peptides of VSG11 and VSG615,
respectively (similar to Fig. 3.2c for VSG3). The determined (VSG11) and the proposed
(VSG615) modified serine residues are indicated within the relevant peptide (the MS/MS data of
the VSG615 glycopeptides did not allow unambiguous assignment of S292 as the unique Oglycosylation site, and thus T291 and S297 could also potentially be sites of modification).
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3.2

Cloning isogenic trypanosome strains expressing wild type VSG3 (VSG3WT) or non-Oglycosylated mutant VSG3 (VSG3S317A)
Because of its central placement on the top surface of VSG3, we wondered whether the

O-linked glycan might affect interactions with the host immune response. To examine this, we
genetically engineered isogenic trypanosome strains that expressed either a wild type VSG3
(VSG3WT) coat or a VSG3 coat with a S317A point mutation (VSG3S317A, which cannot be Oglycosylated). First, VSG3 was cloned into the pUB39166 vector, and the S317A mutation was
introduced by quick-change PCR. The pUB39 vector inserts included genes into the T. brucei
rDNA spacer, where they are expressed under control of a Tet operator. The VSG3S317A mutant
construct was transfected into VSG2-expressing (SM) trypanosomes to test that the mutant
protein could be expressed and presented on the cell surface (alongside the endogenous VSG2)
and recognized by our anti-VSG3 antibody. This test was successful, and the VSG3WT and
VSG3S317A genes were then cloned into the pSY37F1D-CTR-BSD vector (described in section
2.3), creating plasmids pKI224-WT and pKI224-S317A, respectively. These plasmids were then
used to transfect VSG2-expressing SM and GPI-PLC-/- trypanosomes, resulting in four clones:
KI.VSG3WT/S317A-1 (SM background) and KI.VSG3WT/S317A-2 (GPI-PLC-/- background). A diagram
of wild type BES1, the pKI224-WT/S317A constructs, and BES1 in the KI.VSG3WT/S317A clones
is shown in Fig 3.5.
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Figure 3.5. Generation of VSG3WT and VSG3S317A knock-in clones.
(a) (Top) Diagram of the active BES (BES1) in VSG2-expressing SM and GPI-PLC-/- cells;
shows the promoter (bent arrow), a VSG pseudogene (ψ), 70 bp repeats (rpts.), the VSG2 cotransposed region (CTR), VSG2, the telomere seed region (TS) and the telomere (circle).
(Middle) The pKI224-WT/S317A constructs containing VSG3WT or VSG3S317A and a blasticidin
resistance gene (BSD) are recombined into BES1 via break-induced replication (BIR) using the
VSG2 CTR for homology. (Bottom) Diagram of resulting BES1 in the VSG3WT/S317A knock-in
clones.
3.3

VSG3-expressing trypanosomes lacking the O-glycan show decreased virulence
We then used these strains to infect naïve C57BL/6J mice. We observed that whereas all

VSG3WT-infected animals succumbed to infection during the first peak of parasitemia (days 6-9
post infection), all but one VSG3S317A-infected animal survived the first peak (Fig. 3.6a). Late
mortality events (after day 10) in this latter mouse group resulted from outgrowth of parasites
that had switched expression to other VSGs. The data in Fig. 3.6a are combined results of two
experiments with independent sets of clones: KI.VSG3WT/S317A-1 and KI.VSG3WT/S317A-2. Both
clone sets individually produced the same result (Fig. 3.6b and c), suggesting that the observed
decrease in parasite virulence resulting from the S317A mutation is not a clone-dependent
artifact. C57BL/6J is an inbred mouse strain, and different mouse strains can display immune
responses with distinct characteristics. To assess whether the observed virulence differential was
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dependent on the host genetic background, I also repeated the infections in an outbred mouse
strain (CD-1). While more mice infected with VSG3S317A trypanosomes succumbed to infection
during the first peak of parasitemia in these infections, the virulence differential was still readily
apparent (Fig. 3.6d).
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Figure 3.6. VSG3-expressing parasites lacking the O-glycan show decreased virulence.
Survival of mice infected with trypanosomes expressing VSG3WT or non-O-glycoslyated mutant
VSG3S317A. Shaded regions represent sequential “peaks” of parasitemia. (a) Combined results
from two experiments with independent trypanosome clone sets (n = 15 mice/group, data from
individual clone sets are shown separately in (b) and (c)). (b and c) Results from infections with
clones (b) KI.VSG3WT/S317A-1 (n = 5 mice/group), and (c) KI.VSG3WT/S317A-2 (n = 10 mice/group).
Mice in (a-c) are C57BL/6J. (d) Results from infections in CD1 mice (n = 6 mice/group; clones
KI.VSG3WT/S317A-1 were used). All statistical analyses were performed using the log-rank
(Mantel-Cox) test.
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We also observed slightly lower peak parasitemia levels in the VSG3S317A infections
compared to the VSG3WT infections (Fig. 3.7a-d). However, growth curves between the wild type
and mutant VSG3 trypanosomes were similar in vitro (Fig. 3.7e and f), suggesting that the
differences observed in vivo were due to host factors rather than clone-intrinsic. We therefore
reasoned that our collective mouse infection data likely reflected a role for the O-linked sugar in
evasion of the host immune response.
O-glycan-mediated impairment of the host’s ability to generate protective antibodies
would make parasites expressing O-glycosylated VSG3 more virulent within the first peak of
infection. Further, VSG-specific IgM can be present at low titers by day 5 post infection40, and
O-glycan-dependent disparity in the efficiency of antibody-mediated clearance at this stage could
account for the observed differences in day 5 parasitemia levels. Another interesting observation
in the day 5 parasitemia data was that parasitemia levels of both wild type and mutant VSG3
trypanosomes were higher in CD-1 mice than in the C57BL/6J mice (Fig. 3.7d compared to a-c).
This apparent mouse strain-dependent effect on trypanosome proliferation could explain why the
CD-1 mice generally succumbed to infection more rapidly than C57BL/6J mice (Fig. 3.6d
compared to a-c).

62

**

109
108
107
106

WT

*

109
108
107

S317A

WT

13

1010
9

107
10

6

105
104

Doubling
Time (h)

0

48

KI.VSG3WT-1

5.77

KI.VSG3S317A-1

5.74

96

144

**

109
108

108

107

107

106

WT

f

1011

Clone

p = 0.0022

10

WT

S317A

S317A

KI.VSG3-2

1012

108

p = 0.1128
N.S.

109

S317A

1014

10

d 10

10

106

106

KI.VSG3-1
10

Trypanosomes / ml

p = 0.0119

Trypanosomes / ml

e

c 10

10

Parasites / ml

p = 0.0059

b 10

Parasites / ml

10

Parasites / ml

Parasites / ml

a 10

1011
1010
109
108
107
106
10

5

104

192

Doubling
Time (h)

Clone

0

KI.VSG3WT -2

7.35

KI.VSG3S317A -2

7.39

48

96

144

Hours

Hours

Figure 3.7. Day 5 parasitemia and in vitro growth rates of VSG3WT and VSG3S317A clones.
(a-d) Parasitemia levels at day 5 post infection. (a) Combined results from two experiments with
independent trypanosome clone sets (n = 15 mice/group, data from individual clone sets are
shown separately in (b) and (c)). (b and c) Results from infections with clones (b)
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KI.VSG3WT/S317A-1 were used). Statistical values were calculated by two-sided Mann-Whitney
test; bars represent median and interquartile range. (e) and (f) comparisons of in vitro growth
rates for (e) the KI.VSG3-1 clone set, and (f) the KI.VSG3-2 clone set.
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3.4

VSG3WT- and VSG3S317A-elicited antibody responses differ in their ability to protect
against cognate parasites
To address the hypothesis that the O-glycan chains impede the host’s ability to generate a

protective antibody response, we performed additional infection experiments in which mice were
pre-immunized prior to parasite challenge. We inoculated mice with UV-irradiated parasites
expressing either VSG3WT or VSG3S317A (clones KI.VSG3WT-2 and KI.VSG3S317A-2, which are
GPI-PLC-/- and therefore retain their VSG coats following irradiation). I had shown previously
that this protocol yields an immune response that mimics the response to the infective parasite
(discussed in section 2.5). We then challenged these mice via injection of live cognate parasites
at day 8 post immunization and monitored mouse blood smears for the presence of trypanosomes
on days 5-8 post-challenge. As shown in Fig. 3.8a, non-immunized mice (the same mice from
Figs. 3.6a and 3.7a above) uniformly presented parasitemia by day 5. We found that preimmunization with VSG3S317A was highly protective, suppressing detectable outgrowth of
cognate VSG3S317A trypanosomes in 83.3% (10/12) of mice (Fig. 3.8a). In contrast, preimmunization with VSG3WT was only marginally protective against cognate VSG3WT
trypanosomes, suppressing outgrowth in 25% (3/12) of mice. All mice that presented parasitemia
either succumbed to infection or cleared the parasites by day 8. The discrepancy in the protective
effect of pre-immunization was also evident in survival differences between the two mouse
groups (Fig. 3.8b). These results provide evidence that the O-linked glycan chains displayed by
VSG3 inhibit the ability of the host antibody response to mediate parasite clearance.
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Figure 3.8. The VSG3 O-glycan limits the protective effects of pre-immunization
(a) Emergence of parasitemia in non-immunized (N.I.) and pre-immunized mice. N.I. data are
from infections shown in Fig 3.6a and Fig. 3.7a (n = 15 mice/group). Pre-immunized mice (n =
12 mice/group) were inoculated with UV-irradiated trypanosomes expressing VSG3WT or
VSG3S317A (Imm. WT or S317A, respectively) on days -8 and -5 relative to challenge. Challenge
injection contained live parasites expressing the same VSG to which the mice were immunized.
Mice were permanently scored as “parasitemia confirmed” when parasites were first detected via
blood smear. (b) Survival of the pre-immunized mice following challenge. Shaded areas
represent sequential peaks of parasitemia.
3.5

The VSG3 O-glycan affects the binding of antibodies to the trypanosome surface
To directly examine the effect of the O-glycan chains on the properties of the host

antibody response, we collected antisera elicited by VSG3WT or VSG3S317A-coated parasites at
day 8 post-infection, when the early IgM antibodies responsible for parasite clearance reach peak
titers. We then performed flow cytometry analysis to assess antisera binding in the context of the
intact parasite surface coat. In accordance with our in vivo results (Fig. 3.8), we found that
VSG3WT- elicited antisera exhibited markedly lower binding against cognate VSG3WT
trypanosomes, as compared to VSG3S317A-elicited antisera binding cognate VSG3S317A
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trypanosomes (Fig. 3.9a and b; additional statistical analyses of these data are described in
section 3.5.1). These antibody binding data thus further support an immunomodulatory role for
the VSG3 O-glycan chains.
Analyses of the cross-reactivities of these polyclonal antisera (Fig. 3.9a and b) did not
suggest a simple mechanistic explanation as to how the heterogeneous VSG3 O-glycan chains
cause elicitation of IgM responses that are poorly functional against cognate VSG3WT coats.
Notably, however, the unusual pattern of VSG3WT-elicited antisera binding VSG3S317A parasites
better than cognate VSG3WT parasites was also recapitulated by our VSG3-specific monoclonal
antibody. This IgG1 class antibody was also raised against VSG3WT but shows higher binding
against VSG3S317A trypanosomes (Fig. 3.9c). Thus, the effect was reproducible among our three
polyclonal antisera and can also be identified at the level of individual antibodies. Ultimately, the
binding patterns as a whole must be dependent on the properties of individual antibodies
comprising the polyclonal antisera, which cannot be predicted a priori (discussed in greater
detail in section 4.5).
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Figure 3.9. VSG3WT-elicited antibodies bind cognate VSG3WT trypanosomes poorly.
(a) Comparison of VSG3WT or VSG3S317A-elicited IgM antisera (a.s.) binding to live VSG3WT or
VSG3S317A-expressing parasites (par.). Binding was measured by the mean fluorescence intensity
(MFI) of parasite samples stained with (1) dilutions of primary antisera and (2) FITC-labeled
anti-mouse-IgM. Data are shown for one antiserum sample per VSG type. (b) Similar to (c) but
with a single dilution (1:2000) of distinct antisera, elicited by infection of multiple mice (n = 3
independent antisera/VSG type). Statistical values were calculated by two-sided t-tests
comparing the sets of three sample MFIs, assuming normal distribution (* 0.01 < p < 0.05, **
0.001 < p < 0.01; bars show mean and SD). For (a) and (b), dotted lines represent background
MFI. (c) Binding of an Alexa488-labeled monoclonal antibody raised against VSG3WT to
trypanosomes expressing different VSGs. VSG2 is an unrelated class A VSG and VSG11 is a
class B VSG that is also O-glycosylated (see Fig. 3.4)
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3.5.1

Statistical analyses of VSG3WT/S317A-elicited antisera binding data
The statistical analyses reported in Fig. 3.9b were performed by two-sided t-tests

assuming normal distribution of MFI data. To deepen this analysis and account for possible
deviation from normal distribution, I performed additional analyses of the underlying flow
cytometry data using R and Prism software. Fig. 3.10a shows the means (MFI) and standard
deviations (SD) of the flow cytometry data presented in Fig. 3.9b, as well as the MFI and SD of
the same flow cytometry data combined by sample type (i.e. independent antiserum samples
grouped). Because flow cytometry sample Ns are so large, a two-tailed t-test or non-parametric
(Mann-Whitney) test of each individual sample compared to each other sample (and each group
compared to each other group) yields a p value < 0.001 for every comparison. These p values
signify real variation between samples, but do not inform the magnitude or relevance of these
variations. Two comparisons offer a more meaningful interpretation: (1) The mean of each
individual WT parasites + WT antiserum sample is at least one SD below the mean of each
individual sample from all other groups, and (2) The mean of the combined WT parasites + WT
antisera group is two SDs below the mean of each other group (calculated using the larger of the
two SDs in each comparison). Therefore, the differences are not only statistically significant (p
values), but the WT cells + WT antisera combination shows meaningfully lower IgM binding
than all other combinations, based on the magnitude of the differences in sample means
compared to the degree of variation within the data.
Fig. 1.10b shows the same data examined differently by regrouping sample MFIs and
performing a nonparametric, two-tailed Mann-Whitney test of each group of 3 samples of the
same type compared to the other 9 samples combined. Through this analysis, the WT cells + WT
antisera combination is the only group that is significantly different from all of the others.
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Figure 3.10. Statistical analyses of VSG3 antibody binding data.
(Left) The mean (MFI) and standard deviation (SD; error bars) of the flow cytometry data shown
in Fig. 4e (three independent antiserum samples per VSG type; one dilution (1:2000) of each).
(Right) MFI and SD of the same flow cytometry data combined by sample type (i.e. independent
antiserum samples grouped). These data are also shown below in tables, which include the
number of cells analyzed (N) in each sample/group. (f) Two-tailed Mann-Whitney test of each
group of 3 samples of the same type compared to the other 9 samples combined (par. = parasites,
a.s. = antisera).
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3.6

Discussion
Altogether, the glycan-dependent discrepancies observed in (1) parasite clearance

following infection (Fig. 3.6), (2) generation of protective immunity from pre-immunization (Fig.
3.8), and (3) cognate antibody binding (Figs. 3.9 and 3.10) strongly indicate that the
heterogeneous VSG3 O-glycan chains aid the parasite in evasion of the host’s humoral immune
response. VSG glycosylation thus appears to represent an additional T. brucei immune evasion
strategy that overlaps with the broader strategy of antigenic variation. Further, the identification
of analogous O-glycans in other VSGs provides evidence that this may be a widespread VSG
modification, but additional research will be required to verify whether the O-glycans in these
VSGs are also immunomodulatory.
Our data suggest that the greater virulence and heightened day 5 parasitemia levels of the
VSG3WT trypanosomes in naïve mouse infections (Figs. 3.6 and 3.7) can be sufficiently
accounted for by glycan-mediated impairment of the host antibody response. In particular, the
marginal protection provided by VSG3WT pre-immunization (Fig 3.8) shows that VSG3WT
trypanosome outgrowth is often poorly inhibited by host antibodies, and it follows that these
parasites would be more capable of overwhelming the host. However, we have not disproven the
possibility that the VSG3 O-glycan chains could also alter trypanosome-host interactions in other
ways, such as affecting parasite localization or interactions with carbohydrate receptors on host
cells. Thus, inhibition of antibody recognition might be the only role of the O-glycan in affecting
parasite virulence, or it could be one of multiple roles.
Finally, the immune inhibitory effect of the VSG3 O-glycan is not entirely unexpected, as
antigen glycosylation has been shown to inhibit immune recognition of other pathogens as well.
Surface antigen glycosylation is a common immune evasion strategy in viruses, and studies have
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demonstrated that these surface glycans can specifically inhibit antibody recognition and the
development of protective antibody responses185,186. Such strategies are also used by bacterial
pathogens. For example, Neisseria meningitidis glycosylates invariant peptidic regions of its type
IV pili in order to avoid immune recognition187.
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Chapter 4
Discussion
4.1

The influence of the VSG coat replacement immune evasion threshold on parasitemia
dynamics and VSG diversity during infection
In Chapter 2, I demonstrate that trypanosomes require ~4.5 days to fully replace their

VSG coats following a genetic VSG switch, and that these cells are only vulnerable to clearance
by early IgM antibodies for, at most, the initial ~29 hours of that period. To fully evaluate the
impact of these results in the context of an infection, we must also consider the timing of the
genetic switch in relation to the establishment of the immune response. It remains unclear
whether regulation of VSG switching is purely stochastic or whether environmental stimuli affect
switching frequency, but the fact that switching occurs in vitro suggests that there is at least
some host-independent, stochastic element to the process118,119. Analyses of infection dynamics
indicate that early VSG-specific IgMs only reach titers capable of clearing non-switched
trypanosomes 5-6 days after the initial stimulus40. Trypanosomes switching very early in
infection or near the beginning of waves of parasitemia may therefore fully replace their VSG
coats before the IgM response becomes effective, so it is possible that infections could persist
even if trypanosomes remained vulnerable for longer portions of the coat replacement process.
However, the limited vulnerability window I have described certainly does impact the
character of each successive wave of parasitemia. The total number of trypanosomes present
within an infected host exponentially increases as a wave of parasitemia reaches its peak.
Whether or not VSG switching is purely stochastic, the absolute number of independent switch
events must also accumulate accordingly nearer to the peak. If all of the parasites that switch up
to 29 hours before a parasitemia peak are able to survive (as opposed to only those that switch
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several days before the peak), this would imply a significantly greater number of switched cells
forming the subsequent wave of parasitemia.
A larger population of surviving switched cells would affect more than just the initial
level of parasitemia in the subsequent peak. The likelihood that any particular new VSG gene
will be expressed following a genetic switch is probabilistically determined41 (section 1.7.6).
Consequently, a greater number of switched cells would also produce a greater diversity of
VSGs expressed amongst those cells. A recent study conducted by our group demonstrated that
VSG expression is highly diverse within individual waves of parasitemia, and that some major
variants comprise large portions of the population, while some minor variants appear only
transiently37. It is possible that high VSG diversity is necessary for selection of the few variants
that will be successful in a given host environment or a given immune environment, particularly
for sustaining long-term infection. The narrow post-switch vulnerability window I describe in
Chapter 2 is not the only mechanism affecting VSG diversity, but it may prove to be an
important contributing factor. Ultimately, the question of whether a more stringent immune
evasion threshold would permit (or disallow) sustained infections cannot be answered with
certainty.
4.2

Antigen density and IgM functionality
In addition to addressing a gap in our understanding of T. brucei pathogenesis, the work

presented in Chapter 2 may hold broader relevance to the basic biology of IgM. It has been
known for many years that IgM binding is generally dependent on polyvalent interactions (i.e.
avidity) and is therefore sensitive to antigen density178. However this is the first study, to my
knowledge, in which antigen has been titrated on the surface of a pathogen, and a relatively sharp,
density-dependent cutoff of IgM functionality has been established in vivo. It is striking that IgM
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can shift from providing strong protection to providing no discernible protection against a
pathogen following only a ~6-fold reduction in cognate antigen density (7.6%/1.3%; clones DE7.6 and DE-1.3; Fig. 2.11), particularly when the antigen is still highly abundant on the cell
surface at the lower density (~130,000 copies/cell). Further examination of intermediate DEclones between DE-7.6 and DE-1.3 could help in determining more precisely where the IgM
functionality threshold lies, and how sharp of a cutoff it is.
IgM plays an important protective role in a number of other immune interactions as well.
Both induced IgM responses and natural IgMs (non-mutated IgMs constitutively produced in the
absence of immune stimulation) form a crucial first line of defense against many pathogens in
addition to T. brucei188-190. Further, although IgM responses are commonly considered to offer
only transient, early immunity against pathogens, they have also been shown to provide longterm protection in the form of persistent antibody titers191, or rapid antibody production following
restimulation of IgM memory B cells190,192. In cancer immunology, circulating natural IgM
antibodies are known to constitute an innate-like surveillance mechanism. These antibodies can
recognize tumor-specific carbohydrate epitopes on aberrantly glycosylated cell surface antigens
and mediate tumor cell death193,194. Lastly, IgM antibodies that recognize autoantigens have been
shown to actually promote tolerance and protect against inflammatory and autoimmune disease,
although the mechanisms underlying these effects are not completely understood195.
Remyelination-promoting self-reactive IgM antibodies have even entered clinical trials for
multiple sclerosis treatment196. I propose that each of these IgM interactions is likely to be
sensitive to antigen density (potentially excepting occasions where an IgM has undergone
affinity maturation or a germline IgM has unusually high affinity for its cognate antigen). My
results in Chapter 2 suggest that a critical antigen density threshold exists for in vivo IgM
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functionality, at least in some cases. The possibility of such an effect should be considered for
other IgM-related studies, particularly in cases where IgM might be used as a therapeutic, or
where relevant antigens might vary in density (e.g. between patients; between cell types; or on a
pathogen surface, as in T. brucei).
4.3

The functional attributes of individual VSGs
In Chapter 3, I describe our discovery of a new form of VSG post-translational

modification (PTM), O-linked glycosylation, which can impair the host’s ability to generate a
protective antibody response against the modified VSG. The identification of analogous glycans
in other VSGs suggests that this may be a shared trait among many VSGs, and may therefore
have a significant impact during T. brucei infections. Perhaps more intriguingly, this discovery
highlights a gap in our current knowledge of the diverse functional attributes of individual VSGs.
While O-glycosylation appears to be somewhat widespread among VSGs, it is still worth noting
that the first distinct type of VSG we chose to characterize contained a novel feature. We may
have been fortunate in our choice, but it is also possible that many VSGs include biochemical
features that have yet to be discovered. There are a wide array of possible PTMs, any of which
could affect the antigenicity of individual VSGs displaying them. Indeed, additional types of
PTMs are known to affect antibody recognition of antigens displayed by other pathogens.
Methylation of the Leptospira interrogans antigen LipL32 has been shown to potently reduce the
reactivity of antisera derived from L. interrogans-infected patients197, and variable
phosphocholine and phosphoethanolamine modifications can alter the antigenicity of the
Neisseria gonorrhoeae type IV pilus structure198. For T. brucei, it is worth considering that some
VSG PTMs could also have the opposite effect of reducing antigenic variability. Antibodies
raised against a PTM on one VSG could recognize the same PTM on a different VSG, although
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such antibodies may or may not provide protective immunity. In any case, the results of our
analyses of the VSG3 O-glycan demonstrate that VSG PTMs can constitute critical antigenic
determinants, and are worthy of further study.
Individual VSGs may also display distinct functional qualities unrelated to their
antigenicity. It has been known for decades that SRA, the T. brucei rhodesiense gene that enables
parasite evasion of the primate innate immune factors TLF1 and TLF2, encodes a VSG-like
protein199. Much more recently, a VSG was identified that is able to confer resistance to the
trypanocidal drug suramin, but only while the trypanosomes are actively expressing the VSG200.
VSGs are not generally assumed to have a function beyond shielding the parasite from antibody
pressure. However, with such a vast range of VSG genes that are constantly recombining by
mosaic formation120, it is perhaps probable that individual VSGs may on occasion develop
functional attributes that are then selected for and improved by evolution. The different
advantageous functions these VSGs could serve are innumerable: they could affect nutrient
uptake, interactions with host cells (immune or otherwise) or other trypanosomes, parasite
propensity to cross the blood brain barrier, parasite localization within host tissues, etc. Some
other pathogens also display variant surface antigens that serve functional roles in addition to
aiding immune evasion. In malaria, members of the PfEMP1 variant antigen family (proteins
exported to the membrane of erythrocytes infected with Plasmodium falciparum) are known to
mediate adhesion to the endothelial lining of blood vessels and direct tropism to different
vascular regions201. Bacteria of the genus Borrelia (including the causative agents of Lyme
disease and tick-borne relapsing fever) also express variant antigens that influence tissue tropism
and patterns of pathogenesis202. In T. brucei, the discovery and characterization of specialized
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functions of individual VSGs represents a virtually unexplored, and potentially fruitful research
avenue.
It is unclear to what extent VSG proteins might display unique biochemical properties or
perform specialized functions. The number of VSGs with solved, high-resolution N-terminal
crystal structures remains very small (four in total, counting VSG3 described here). Increasing
efforts to biochemically characterize or solve the structures of additional VSGs would help in
determining the full diversities of VSG structural features and PTMs. One screening method to
identify VSGs of interest could be to incubate diverse trypanosome populations with antibodies,
lectins, or other agents that specifically recognize known PTMs, and isolate trypanosomes
expressing these modifications via flow cytometry sorting (FACS) or immunoprecipitation. Of
course, this method would only be feasible for those modifications for which such reagents were
available. With regard to discovering novel VSG functions, specific traits would likely have to
be screened individually. For example, sequencing the VSGs present in trypanosomes extracted
from different mouse tissues could indicate whether any VSGs are enriched in a certain area,
potentially providing evidence of VSG-based parasite tropism. Altogether, determining the true
extent of functional and biochemical variability between VSGs would be a worthwhile endeavor
to improve our understanding of T. brucei antigenic diversity and disease pathogenesis, with
potential implications for other pathogens as well.
4.4

VSG cross-reactivity and antigenic diversity in sustained infections
While high diversity in VSG expression may be advantageous for ensuring selection of a

VSG appropriate for a given environment, it also exposes the VSG repertoire to the host immune
system more rapidly, which could exhaust the total antigenic diversity available to the parasite.
However, several pieces of evidence suggest that exhaustion of the VSG repertoire may not pose
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a significant constraint on long-term trypanosome infections. First, the basic fact that VSG
expression is highly diverse during infection37 indicates that infections can persist with a high
rate of exposure of distinct VSGs. Secondly, T. brucei gambiense infections in humans and other
African trypanosome infections in animals can persist up to several years before death of the
host1,2. This suggests that (1) trypanosomes are capable of continually developing sufficient
antigenic diversity over extremely long periods (via mosaic VSG formation), or (2) the
immunosuppressive methods trypanosomes employ make sustained antigenic diversity less
important, or even unnecessary. The full long-term immune evasion mechanism almost certainly
relies on both of these factors, but the relative importance of each factor at different stages of
infection remains unclear.
Examination of antisera cross-reactivity patterns between VSGs may provide insight into
the extent of VSG diversity required to continually evade the host antibody response. One way to
explore this (similar to my proposal for identifying PTMs above) would be to (1) raise
polyclonal antisera against multiple VSGs, (2) incubate the individual antisera with trypanosome
populations expressing many VSGs, (3) isolate the bound trypanosomes by FACS or
immunoprecipitation, and (4) sequence the isolated parasites to determine what features were
shared between cross-reactive VSGs. Such analyses should take into account the possibility that
homologous VSG regions could be antigenically distinct due to variable PTMs, and shared
PTMs could lead to cross-reactivity between otherwise dissimilar VSGs. Mosaic VSGs are
particularly intriguing with regard to cross-reactivity. These VSGs are created by segmental gene
conversion events that accumulate donor VSG segments over time, and some related mosaic
VSGs containing homologous regions are antigenically distinct120 (see section 1.7.4). Crossreactivity between related mosaic VSGs could also be examined by the method described above
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or by similar methods. If these types of analyses were combined with structural information, they
could also provide direct insight into which VSG regions were accessible to or commonly
targeted by host antibodies.
A number of observations suggest that T. brucei interactions with host immunity change
significantly in late stages of infection. As infection progresses, depletion of various B cell
populations occurs156,158,160, and after several weeks, infected mice display poor stimulation of
secondary (memory) antibody responses and poor control of infectious agents that they have
previously developed immunity against159,160 (discussed in section 1.8.4). Further, while periodic
waves of parasitemia are hallmarks of early T. brucei infection (due to cycles of successive
antibody responses and parasite clearance), this distinct periodicity often breaks down at late
stages, suggesting that parasite-antibody interactions are qualitatively different at these time
points37,41. Examination of VSG expression in late stages of infection has shown that although
populations expressing a given VSGs can persist for longer periods, they are often still cleared at
some point37. This pattern indicates that VSG-specific antibody responses can still be generated
late in infection, albeit less rapidly and perhaps less comprehensively. Thus, immune suppression
alone may not be sufficient to ensure escape from antibody pressure, and the parasite may
require continuous antigenic variation even at late stages. One way to examine this could be to
challenge mice late in infection with pleomorphic trypanosome strains that are incapable of
switching their VSG coat (e.g. by expressing a VSG at an ectopic location). If these parasites
were able to persist for long periods, it would provide evidence that antigenic variation is not
required at late infection stages. However, the tools to perform the necessary genetic
manipulations of pleomorphic strains do not exist at present, and the high virulence of
genetically tractable monomorphic strains would limit their utility for this purpose.
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4.5

Mechanism of VSG3 O-glycan-mediated impairment of the antibody response
The binding properties of VSG3WT- and VSG3S317A-elicited antisera (referred to in this

section as WT and S317A antisera, respectively) against VSG3WT- and VSG3S317A-expressing
trypanosomes (WT and S317A parasites, respectively) suggest a complicated mechanism for the
immunomodulatory effect of the O-glycan chains. The fact that WT antisera bind S317A
parasites well weakens the explanation that the O-glycan simply causes elicitation of antibodies
that are poorly functional. In the reverse combination, the strong binding of S317A antisera
against WT parasites indicates that the O-glycan is not broadly able to inhibit antibody binding.
These data therefore suggest that the poor binding of the WT/WT parasite/antisera combination
may result from a combined effect of the O-glycan at both the antibody elicitation stage and in
the subsequent antibody-parasite interactions.
It is important to discuss the potential effects of O-glycosylation on the epitope repertoire
of VSG3. The most intuitive scenario is one where the glycan simply occludes an epitope in
VSG3WT that is then exposed when the glycan is removed in VSG3S317A. However, the full effects
of the glycan may vary considerably depending the precise binding specificity of a given
antibody as well as the interactions of the glycan with surrounding peptidic regions of VSG3
itself. This is succinctly summarized in an excerpt from a review by Lisowska (2002):
“Glycoproteins may elicit antibodies against defined carbohydrate structures,
which are recognized irrespective of their carrier protein or in the context of their
location in the antigen polypeptide chain. Moreover, N- and O-glycans frequently
modulate the activity of adjacent peptidic epitopes due to intramolecular
carbohydrate-protein interactions [...] The presence of glycan(s) may not only
enhance or decrease the reactivity of the peptidic epitope (quantitative change),
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but may also form a neoepitope or abolish the reaction (qualitative effect). There
are no distinct rules as to which monosaccharide components of N- or O-glycans
are most important for these effects… various components or fragments of the
oligosaccharide chain may exert different (sometimes opposite) effects.”203
In other words, glycans can create a set of epitopes that are distinct from those presented
by the aglycosylated protein, and these altered epitopes may not necessarily contain the glycan
itself. Subsequently, a given antibody raised against a glycoprotein may have unaffected,
increased, or decreased binding affinity based on (1) the presence or absence of the glycan, (2)
the length and composition of the glycan chain, and (3) the allosteric effect of the glycan on the
structural conformation of the surrounding peptide regions (which may also vary based on the
length and composition of the glycan chain). The impact of differential glycosylation can vary
dramatically and unpredictably for individual antibodies. One recent study, which examined the
binding patterns of a set of monoclonal antibodies against variably glycosylated peptides of the
protein MUC1, provides examples of such effects204.
In the case of VSG3, our data suggest that O-linked glycosylation produces, minimally,
four antigenically variable entities on the trypanosome surface: VSG3 can be decorated with 0, 1,
2 or 3 hexose units linked to S317 (at an estimated ratio of 8%, 33%, 37%, and 22%,
respectively). We have also found that these hexoses, though anchored to the VSG by an Olinked glucose, may contain both glucose and mannose moieties (with the exact percentages of
each and linkages still under investigation). Such alternative stereochemistries of glycans have
also been shown to alter their protein binding properties205. Additionally, IgM antibodies (the Ig
class of relevance to these studies), are particularly sensitive to epitope density (see Chapter 2).
The presence of various glycoforms on a VSG3WT coat could reduce the effective densities of
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any epitopes altered by glycosylation, while a VSG3S317A coat would be comparatively
homogenous and potentially more amenable to binding for IgMs with certain specificities.
Overall, the effects of glycosylation make VSG3WT more antigenically diverse than
VSG3S317A. Non-O-glycosylated VSG3 possesses only one set of epitopes. Mono-, di-, and triglycosylated VSG3 each possess a partially altered set, with each additional sugar group varying
the peptide and glycan epitopes presented to an unknown degree. This variability could affect
both the comparative immunodominance of epitopes in antibody elicitation and individual
antibody binding patterns against the varied epitopes (i.e. antibodies may effectively bind some
glycoforms but not others). Bearing these uncertainties in mind, there may be highly antigenic
peptidic epitopes presented in the WT parasites that are still presented to a lesser degree in the
WT (e.g. only in certain glycoforms) than in the S317A parasites. The properties of our VSG3specific monoclonal antibody provide evidence for such a scenario, as this antibody was raised
against WT parasites and appears to recognize a peptidic epitope common to VSG3WT and
VSG3S317A, but binds S317A parasites more strongly (Fig. 3.9c).
Ultimately, it is not possible to predict, a priori, the prevalence of elicited antibodies in
our antisera with given binding epitopes, glycoform specificities, and affinities, but these are the
factors that underlie our binding results in aggregate. The determination of a detailed mechanism
for the data we observe would therefore require additional research, most likely including the
cloning of individual IgM antibodies elicited against VSG3WT and VSG3S317A and comparing
their binding patterns against individual intact VSG3 glycoforms, or possibly VSG3 peptide
glycoforms.
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Chapter 5
Methods
5.1

Trypanosome cell lines

All trypanosome cell lines were bloodstream-form trypanosomes ultimately derived from the
Lister427 “single marker” (SM) cell line167. Trypanosomes were cultivated in HMI-9 medium
with 10% fetal bovine serum (Sigma F4135) at 37°C and 5% CO2. “WT-VSG2” trypanosomes
are unaltered SM cells. Derivation of the D70 clone has been described previously43. The WTVSG3 clone used in Chapter 2 was isolated from a group of switched cells from the 70.II line
published by Hovel-Miner et al.43. In this clone, VSG3 is the active VSG gene expressed from
Bloodstream Expression Site 1 (BES1). The D70 and WT-VSG3 clones were provided by Dr.
Galadriel Hovel-Miner (current address: George Washington University). VSG2-expressing
trypanosomes lacking GPI-PLC (GPI-PLC-/-)84 were provided by Dr. George Cross (Rockefeller
University). Methods of generating the additional transgenic cell lines used in this thesis are
described in individual sections below.
5.2

Monoclonal anti-VSG antibodies

The monoclonal anti-VSG antibodies used in these studies were produced by the Antibody and
Bioresource Core Facility of the Memorial Sloan Kettering Cancer Center. The anti-VSG2
antibody is clone VSG221-31G9, while the anti-VSG3 antibody is clone VSG224-11D6 (both
publicly available
[http://macfwebext.mskcc.org/EstablishedMAb/SearchEstablishedMAbs.aspx]). Only these two
clones were used, but experiments were performed using individually prepared antibodyfluorophore conjugates (the fluorophore conjugates used in each experiment are indicated in
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methods and figure legends). These antibody-fluorophore conjugates were generated using
purified antibody and Invitrogen protein labeling kits, following manufacturer instructions
(Alexa647 A20173; Alexa488 A10235; Pacific Blue P30012; FITC F10240).
5.3

Engineering sortaggable VSG2 (VSG2STa) and VSG2STa knock-in clones

The amino acid sequence GGGENLYFQGGGGGG was cloned into VSG2 (GenBank X56762)
replacing residues E29-G31165. This segment immediately follows two Ala residues which form
the N terminus of the mature VSG2 protein after the preceding leader peptide sequence is
removed163 (thus the mature VSG2STa protein begins
AAGGGENLYFQGGGGGGFKQAFWQPLCQVS-, insertion underlined). The original plasmid
construct for VSG2STa knock-in, pSY37F1D-CTR (derived from pSY37206, a gift of Dr. Heesook Kim; current address: Cleveland State University), contains in order: 1156bp of the
“cotransposed region” (CTR) preceding the VSG2 open reading frame in BES1 of the Lister427
genome, immediately followed by the previously described VSG2STa gene, then a Hygromycin
resistance gene (HYG), and finally a 200bp telomere seed region. A BglII restriction site was
used to linearize the plasmid, leaving the CTR and telomere seed on opposing ends of the
resulting DNA fragment. This fragment was then used for transfection of WT-VSG2 (SM) cells
via the Amaxa nucleofector protocol as previously described207, resulting in clone KI-VSG2STa.
To knock VSG2STa into D70 cells (which are already hygromycin resistant), a new plasmid
construct (pSY37F1D-CTR-BSD) was created by introducing a blasticidin resistance gene
(BSD) in place of HYG. Plasmid linearization and transfection were performed as above,
resulting in clone D70STa. In both cases, the transfection replaces the previously active VSG2
gene, such that KI-VSG2STa and D70STa express only VSG2STa.
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5.4

Sortase A purification

Plasmid containing the S. pyogenes-derived sortase A expression construct (pSpSortApET28a208, a gift of Dr. Assaf Raz, Rockefeller University) was transformed into BL21 DE3
cells (Life Technologies C6000-03). Colonies from this transformation were used to inoculate
large cultures of LB media (VWR 1.10285.0500) and grown shaking at 37°C to an optical
density (OD600) of 0.4 - 0.8. Cultures were then induced with 1mm IPTG, grown an additional 34hr, and harvested by centrifugation. Cell pellets were resuspended in TBS/imidazole (20mM
Tris, 150mM NaCl, 20mM imidazole), and lysed using an EmulsiFlex-C5 homogenizer
(Avestin). DNAse-A powder (Sigma D5025) and 5mM BME were added to the lysate, and it
was centrifuged to remove particulate. The supernatant was poured over a column of Ni
chelating beads (Qiagen D-40724) which had been equilibrated with wash buffer (20mM Tris,
300mM Nacl, 20mM imidazole, 5mM BME). The column was washed with 100ml wash buffer
and eluted with 30-35ml elution buffer (20mM Tris, 300mM NaCl, 200mM imidazole, 5mM
BME). Samples containing protein were pooled and dialyzed in (20mM Tris, 150mM NaCl,
1mM DTT). The resulting sample was concentrated using a centrifugal filter unit (Amicon Ultra
– 10,000 NMWL, Millipore), aliquoted, and frozen for future use.
5.5

Sortagging reaction

FITC (5-FAM; 5-carboxyfluorescein), nitrophenol (NP) and TAMRA-peptide conjugates
([FITC]/[NP]/[TAMRA]-GGGSLPSTGG, sortase recognition motif underlined) were
synthesized by Elim Biopharmaceuticals. Sortagging solutions containing 100uM purified
Sortase A and 300-600uM peptide conjugate [Concentration varied between experiments of
different types, but was consistent for replicates of the same experiment] in HMI-9 media were
incubated on ice for 30-60min. Trypanosomes expressing VSG2STa were pelleted, resuspended in
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the sortagging solution, and incubated for 1 hr at 4°C on an inversion rotator. Cells were then
pelleted, washed once with HMI-9 media, and pelleted again before final resuspension in HMI-9.
These cells were then analyzed immediately or returned to normal culture conditions. For Fig.
2.2, ectopic expression of VSG2STa was induced by adding 100 ng/ml Dox to culture media 24
hrs before isolating cells for sortagging reaction. For Fig. 2.4a, NP-tagging of trypanosomes was
visualized after staining with Alexa647-labeled anti-NP antibody (Genway Biotech GWB4C4D87). For Fig. 2.5b, Sortagged KI-VSG2STa cells were cultured for 12 hrs prior to imaging.
Imaging was performed using an ImageStream-X flow cytometer (Amnis). For Fig. 2.5c,
sortagged KI-VSG2STa cells were isolated from culture at indicated time points and analyzed via
BD-FACSCalibur flow cytometer.
5.6

Southern blot
Trypanosome Genomic DNA was isolated using DNAzol (Invitrogen 10503-027)

following manufacturer protocol, and 10 ug of this DNA was digested overnight with 200 U
SmaI restriction enzyme. Digested DNA was extracted by phenol/chloroform using MaXtract
Low Density columns (Qiagen). This DNA was then run on a 0.8% TAE agarose gel for 12 h at
50V. DNA was denatured and transferred to Amersham Hybond-N+ membrane (GE Scientific)
by capillary blotting according to manufacturer instructions, and UV-crosslinked using a FBUVXL-1000 UV crosslinker (Fisher Scientific). VSG2 32P-radiolabeled probe was produced by
PCR amplification using the Prime-It II Random Labeling Kit (Stratagene). Blot was hybridized,
washed, and visualized using a phosphoroimaging apparatus and Typhoon Scanner (GE
Healthcare).
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5.7

Trypanosome clone growth rate analyses

Trypanosomes were diluted to 105 cells/ml in culture. Cell concentration was analyzed every 24
hours, and cultures were diluted back to 105 cells/ml immediately after measuring concentration.
Total cell number was calculated by multiplying the concentration each day by the dilution
factors of each previous day.
5.8

Conversion of MFI values to MESF values

Quantum FITC and Alexa647 MESF bead kits (Bangs Laboratories cat. 555 and 647) were used
to convert sortag (FITC) or anti-VSG2-antibody stain (Alexa647 conjugate,1:2000 dilution) raw
mean fluorescence intensity (MFI) values to absolute Molecules of Equivalent Soluble
Fluorochrome (MESF) units172 per manufacturer instructions. For each fluorophore, a set of
Quantum beads were run on the flow cytometer immediately prior to trypanosome sample
acquisition, using identical settings. These bead sets consisted of 5 or 6 samples of beads, each of
which were conjugated to a known amount of fluorophore. Bead MFI values were then entered
into Bangs Laboratories software provided with the kits, which generated a calibration curve for
converting MFI of other samples to MESF units. MFI values from trypanosome samples were
then entered into this same software to obtain absolute MESF values.
5.9
5.9.1

VSG coat replacement: visualization and rate calculation
Switch induction for Δ70 and Δ70STa cell lines

Δ70 or Δ70STa trypanosomes were diluted to 105 cells/ml in culture flasks containing HMI-9 with
1ug/ml Doxycycline (Dox), then incubated in normal culture conditions for 6 hrs. At 6 hrs, cells
were pelleted, washed with Dox-free HMI-9, then resuspended in Dox-free HMI-9 and incubated
again in normal culture conditions. Non-induced cells were treated identically, except without
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Dox in the initial 6 hr incubation. For sortagging/switching experiments (Fig. 2.6), Δ70STa cells
were sortagged as described in section 5.5 (using 600uM 5-FAM-peptide) immediately prior to
switch induction.
5.9.2

Flow cytometry sample preparation

All of the following samples, solutions, and incubation steps were at 4°C or on ice to prohibit
antibody internalization during sample preparation. Samples of 2 x 106 trypanosomes were
isolated from induced or non-induced cultures, pelleted, and resuspended in HMI-9 containing
monoclonal antibodies recognizing VSG2 (the pre-switch VSG, antibody was anti-VSG2Alexa647 [1:2000 dilution]) and VSG3 (one of many post-switch VSGs, antibodies were antiVSG3-Alexa488 [1:400 dilution] or anti-VSG3-Pacific Blue [1:100 dilution]). Samples were
incubated on an inversion rotator for 10 min, then pelleted and washed once with HMI-9.
Samples were then pelleted again, resuspended in HMI-9 containing 500ng/ml Propidium Iodide
(BD 556463), and analyzed using a BD-FACSCalibur (Fig. 2.1) or BD-LSRII (Fig. 2.6) flow
cytometer. Single-stain samples for flow cytometry compensation were prepared identically
using the same antibody and Propidium Iodide concentrations, CFSE staining, or sortagging
procedures.
5.9.3

VSG tE1/2 calculations

Flow cytometry data was analyzed using FlowJo software. Trypanosome populations were gated
via forward and side scatter, then dead cells were excluded by gating cells negative for
Propidium Iodide staining. tE1/2 values were calculated from data from the 12 hr post-induction
time point onward, because the presence of cells expressing switched VSGs (see VSG3-positive
cells in Fig. 2.1c) indicated that the genetic VSG switch had occurred by this point, and thus
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VSG coat replacement was actively taking place. “Switcher” populations were gated from “nonswitcher” populations by anti-VSG2 antibody staining (Alexa647 conjugate,1:2000 dilution; see
Fig. 2.6a) for 24 hr – 48 hr time points. For the 12 hr time point, the switcher and non-switcher
populations were not gated separately, because at this early stage the switchers had not lost
enough VSG221 to be identified as distinct from the non-switchers. MFI values from switcher
and non-switcher populations were converted into MESF units as described in section 5.8, and
tE1/2 values were calculated via non-linear regression analysis using Prism software.
5.10 CFSE cell proliferation analysis
Immediately following sortagging reaction (section 5.5), trypanosomes were pelleted and
resuspended in CFSE buffer (PBS, 0.1% BSA, 154mM Glucose), then added to solutions
containing CFSE buffer with 800nM (final concentration) CFSE (Invitrogen C34554). Samples
were incubated for 15 min at 37°C, then the reaction was quenched by adding the entire volume
to 5x volume of HMI-9 and incubating for 5 min at room temperature. Cells were pelleted and
washed once with HMI-9, then induced to switch (section 5.9.1) or returned to normal culture
conditions. Sample collection and preparation, and flow cytometry gating were performed as
described above.
5.11 Generation and characterization of DE clones
5.11.1 Construct cloning and transfection
Simultaneous expression of two VSGs from the active Bloodstream Expression Site (BES) has
been described previously175. For my constructs, a ~1kb stretch of unique intergenic region
(UIR) from Lister427 BES1 was amplified from WT-VSG2 genomic DNA (gDNA) using
primers JPC1_UniqueFor and JPC2_UniqueRev, while a pUC19 backbone was amplified using
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primers JPC3_pUC19For and JPC4_pUC19Rev (see section 5.20 for primer sequences). These
PCR fragments were digested with XhoI and BglII and ligated to create plasmid pJP01. The UIR
contains a BsaAI blunt end restriction site near the center of the region that was used for
subsequent cloning steps. pJP01 also contains NotI restriction sites flanking the UIR, which
allow release of this fragment.
For each DE clone construct, the VSG2 gene, its flanking UTRs, and a BSD resistance cassette
were cloned into the pJP01 vector (cut at the BsaAI site in the center of the UIR) by Gibson
assembly (cloning kit: NEB E5510S) using PCR fragments with 30bp of overlapping homology
at the junctions. The resulting plasmids were digested with NotI and transfected into parental
clone WT-VSG3 via the Amaxa nucleofector protocol as previously described207. Cloning details
for each specific clone are described in the next section, and primer sequences are shown in
section 5.20.
5.11.2 Cloning details
1) Clone DE-1.3 (plasmid pJP04):
The modified procyclin (Procyclin (mod)) 5’UTR was based on the pNS10/54 5’UTR published
by Siegel et al.173. It was created by assembly PCR using overlapping oligos, followed by
insertion into a pGEM backbone. The full Procyclin (mod) sequence is shown below. This
5’UTR was amplified with primers JPC18_GibsonP2For and JPC19_GibsonP2Rev. The VSG2
sequence was amplified from pSY37*206 with primers JP09_VSG221_For and
JPC24_GibsonP3221UTR_Rev. The BSD cassette (BSD gene with surrounding actin 5’ and
3’UTRs) was amplified from pHJ37-BSD (derivative of pHJ37*, unpublished) with primers
JP11_ACT5UTRStart_For and JPC22_GibsonP5Rev.
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2) Clone DE-7.6 (plasmid pJP05):
VSG2 with its 5’ and 3’ UTRs was amplified from pSY37* with primers
JPC26_GibsonP3221UTR_For and JPC24_GibsonP3221UTR_Rev. The BSD cassette was
amplified as in clone DE-1.3.
3) Clone DE-11 (plasmid pJP07):
The Aldolase 5’UTR was amplified from pSY37* with primers JPC31_JP07P2_For and
JPC32_JP07P2_Rev. VSG2 was also amplified from pSY37 with primers JP09_VSG221_For
and JPC20_GibsonP3Rev. The Aldolase 3’UTR was amplified from pLEW100*167 with primers
JP10_Ald3UTR_For and JPC21_GibsonP4Rev. The BSD cassete was amplified as in clones DE1.3 and DE-7.6.
*These plasmids were provided by Dr. Hee-sook Kim (current address: Cleveland State
University)
5.11.3 Analysis of VSG surface expression levels
VSG2 and VSG3 surface expression were measured by quantitative flow cytometry analysis.
Flow cytometry samples were prepared as described in section 5.9.2, with the following
exceptions: Samples for Fig. 2.9b and c were prepared using single anti-VSG3 antibody
solutions diluted as indicated. For Fig. 2.8b and Fig. 2.9a, samples contained 3 x 104 cells of the
indicated clone, pelleted along with 106 WT-VSG3 cells. This permitted use of a saturating antiVSG2-Alexa647 antibody concentration (1:100 dilution, see Supplementary Fig. 2a), because
fewer VSG2-expressing cells were present to draw antibody out of solution. The additional WTVSG3 cells allowed effective pelleting of such small samples of the VSG2-expressing clones.
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Saturating levels of anti-VSG2-Alexa647 antibody were necessary to ensure that limiting
antibody concentration did not skew relative surface VSG2 expression measurements.
For Fig. 2.9b, Conversion to MESF units was performed as described in section 5.8 to convert
raw fluorescence intensity data to absolute values. The background MESF value (from cells with
no antibody staining) was subtracted from the sample MESF values to generate “MESF-BG”
values. VSG percentages were calculated as the DE clone MESF-BG divided by the WT-VSG2
MESF-BG. MESF calculation was not performed for Fig. 2c, because relative staining levels were
sufficient to assess VSG2 expression stability over time. All samples for Figs. 2.8 and 2.9 were
analyzed using a BD-LSRII flow cytometer. For data analysis (using FlowJo software),
trypanosome populations were gated via forward and side scatter, then dead cells were excluded
by gating cells negative for Propidium Iodide staining.
5.12 Generation of isogenic VSG3WT and VSG3S317A-expressing clone sets
The wild type VSG3 and VSG3-S371A point mutant genes were transfected into trypanosomes by
means of the pSY37F1D-CTR-BSD vector209 described in Chapter 2. This vector contains a
blasticidin-resistance gene (BSD) cassette and allows a “knock-in” transfection in which the VSG
gene included in the vector replaces the endogenous VSG2 gene in the telomeric Bloodstreamform Expression Site 1 (BES1) of the Lister427 genome (see diagram, Fig. 3.5).
5.12.1 Plasmid cloning
Plasmid cloning was performed as follows: first, the wild type VSG3 gene was amplified from
trypanosomal genomic DNA (Lister 427) into a pGEM subcloning vector (Promega A1360), and
the S317A mutation was introduced by QuickChange PCR. Wild type and mutant VSG3 genes
were then cloned into the vector pUB39166 (replacing VSG117 in the original vector via HindIII
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and BamHI sites) to create pSUN7 and pSUN8. VSG3 and VSG3-S317A were amplified from
pSUN7 and pSUN8, respectively, using primers 224_BsiWI_For
(GCGACACGTACGCGGCATGCAAGCGGCAGCA) and 224_AvrII_Rev
(AATTAACCTAGGGGGCAATTCCAGCTGTC) (these PCR fragments contained the
WT/S317A VSG3 coding regions along with the surrounding VSG117 5’ and 3’ UTRs from the
pUB39 vector). The backbone vector pSY37F1D-CTR-BSD was digested with BsiWI and SpeI,
and the larger fragment was isolated by gel purification. VSG3 and VSG3-S317A PCR fragments
were digested with BsiWI and AvrII and ligated into the pSY37F1D-CTR-BSD backbone
fragment, resulting in final plasmids pKI224 and pKI224-S317A, respectively.
5.12.2 Transfections and resultant clones
These plasmids were then linearized with XhoI and transfected into a parental clone expressing
VSG2 via the Amaxa nucleofector protocol as previously described207. BSD resistant clones
were selected based on expression of VSG3 (by FACS) and counterselected for dual expressors
(which co-expressed VSG2; also by FACS), using monoclonal antibodies to VSG2 and VSG3.
VSG2 counterselection was used to eliminate a subset of clones which integrated the VSG3
cassette ectopically. Two sets of clones were generated. Transfection of VSG3 and VSG3-S317A
into the Lister 427 “single marker” cell line167 produced clones KI.VSG3WT-1 and KI.VSG3S317A1, respectively. Transfection of VSG3 and VSG3-S317A into a different VSG2-expressing Lister
427 cell line (GPIPLC null,84) produced clones KI.VSG3WT-2 and KI.VSG3S317A-2, respectively.
KI.VSG3WT-2 and KI.VSG3S317A-2 were thus generated on a GPIPLC-/- background. The lack of
a GPI-PLC gene does not affect parasite virulence or the course of parasitemia84, and
consequently should not affect interpretation of the mouse infection results shown. The presence
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of the single point mutation within VSG3S317A was verified in the KI.VSG3S317A clones through
RT-PCR amplification and sequencing.
5.13 Immunization of mice with UV-irradiated GPI-PLC-/- trypanosomes
VSG2, VSG3WT, or VSG3S317A-expressing GPI-PLC-/- trypanosomes were pelleted from culture,
washed with irradiation buffer (PBS, 154mM Glucose), and resuspended in irradiation buffer to
a density of 107 cells/ml. 1ml of this resuspension was aliquoted into each well of a 6 well tissue
culture plate (Falcon 353046). Plates were UV-irradiated for 10 min in 1 min intervals using a
FB-UVXL-1000 UV crosslinker (Fisher Scientific). Plates were swirled between 1 min intervals
to ensure equal irradiation of trypanosomes. Irradiated cells were pelleted and resuspended in
HMI-9 at desired concentration, and 100ul of this solution was injected i.p. into mice. This
immunization procedure was performed twice on each mouse on day 0 and day 3 (except while
initially testing immunization methods; shown in Fig.2.10b). For experiments shown in chapter
2, immunization injections contained 3 x 106 UV-irradiated trypanosomes. For experiments
shown in chapter 3, immunization injections contained 2-3 x 106 UV-irradiated trypanosomes.
For live trypanosome comparison immunizations (Fig. 2.10c), mice were infected on day 0 with
100 or 1000 live WT-VSG2 trypanosomes via i.p. injection. Infections were cleared with 250ng
berenil/mouse injected i.p. on the day trypanosomes were identified by blood smear (day 4 for
1000 injected, day 5 for 100 injected). Berenil treatment was repeated 24 hours after initial
treatment. Serum samples for ELISA analysis were obtained via submandibular bleed, and serum
was separated from whole blood using Microtainer serum collection tubes (BD 365967).
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5.14 Mouse infection and immunization-challenge experiments
5.14.1 Chapter 2
All mice were female, wild type C57BL/6J, aged 6-9 weeks at experiment start (Jackson
Laboratory). Mice were immunized with UV-irradiated VSG2-expressing GPI-PLC-/trypanosomes, and serum samples were obtained for ELISA analysis (from immunized and nonimmunized control mice) on day 8 post-immunization as described above. Later that same day,
mouse groups were challenged via i.p. injection of 100 live WT-VSG2, WT-VSG3, DE-11, DE7.6, or DE-1.3 trypanosomes in HMI-9. Mice were monitored for survival twice daily on days 4
– 16 post-challenge, then once daily until day 23. Mice were also monitored for trypanosome
infection by blood smear (blood from mouse tail clippings was examined by eye under a
microscope for the presence of trypanosomes), and permanently scored as “confirmed infected”
once trypanosomes were identified, regardless of whether parasitemia subsequently fell to
undetectable levels. Blood smear monitoring occurred daily from days 4 – 8 post-challenge (i.e.
through the first peak on infection) for all mice. After day 8, all mice that had not yet exhibited
parasitemia were monitored daily until the mouse died or the experiment ended. At all times, if
blood smears indicated a quantifiable level of parasitemia, parasitemia was measured using a
hemocytometer. One mouse in the non-immunized DE-11 group was excluded from analysis
because ELISA results showed high anti-VSG2 IgM titers despite lack of immunization, and one
mouse in the immunized DE-7.6 group was excluded because it died during the course of the
experiment from a cause unrelated to trypanosomiasis. All animal experiments were approved by
Rockefeller University’s institutional animal care and use committee under protocol #16894.
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5.14.2 Chapter 3
All mice were wild type males or females, aged 6-9 weeks at experiment start (Jackson
Laboratory). For Figs. 3.6 and 3.7a-d, groups of C57BL/6J or CD-1 mice were infected via i.p.
injection of 100 live trypanosomes expressing either VSG3WT or VSG3S317A. For Fig. 3.8,
C57BL/6J mice were immunized with UV-irradiated trypanosomes as described in section 5.13
(using clones KI.VSG3WT-2 or KI.VSG3S317A-2). The subsequent challenge injection was
administered 8 days after the initial immunization, and consisted of 100 live trypanosomes (as in
the naïve mouse experiments). For all infection experiments, mouse survival was assessed daily,
and parasitemia was monitored starting on day 4 or 5 by blood smear (blood from mouse tail
clippings was examined by eye under a microscope for the presence of trypanosomes) or by
counting parasite numbers using a hemocytometer. For Fig 3.8a, mice were permanently scored
as “confirmed parasitemia” when parasites were first identified by blood smear, regardless of
whether parasitemia subsequently fell to undetectable levels. All animal experiments were
approved by Rockefeller University’s institutional animal care and use committee under protocol
#16894.

5.15 Analysis of VSG expression in infection isolates
Trypanosomes were isolated from mouse blood during some infections for flow cytometry-based
VSG expression analysis. For these analyses, 100 ul infected mouse blood was collected and
incubated twice with 1 ml Red Blood Cell Lysing Buffer (Sigma R7757) for 4 minutes at room
temperature. Samples were then resuspended in 100 ul HMI-9 with a 1:50 dilution of Mouse FC
Block (BD 553142) and incubated on an inversion rotator for 10 minutes at 4°C (all subsequent
steps were on ice or at 4°C). 10 ul of each sample was then added to 100 ul of HMI-9 containing
96

anti-VSG2-Alexa647 (1:1000 dilution) and anti-VSG3-Alexa488 (1:200 dilution) antibodies.
These solutions were incubated on an inversion rotator for 10 minutes, pelleted, and washed once
with 1 ml HMI-9. Samples were then pelleted again, resuspended in 200 ul HMI-9, and analyzed
using a BD-FACSCalibur flow cytometer. Control WT-VSG2 and WT-VSG3 samples were
pelleted from culture and stained identically with the same anti-VSG2 and anti-VSG3 antibody
dilutions.
5.16 ELISA assays
ELISA assays were performed using established methods. ELISA plates (Corning 9018) were
coated with 2.3 ug/ml purified VSG2 in borate buffer (100mM Boric Acid, 25mM Sodium
Borate, 75mM Sodium Chloride), then blocked with blocking buffer (1% BSA in borate buffer).
Primary antibody solutions contained 1:30 (Fig. 3a) or 1:100 (Supplementary Fig. 3a) dilutions
of mouse antisera in blocking buffer. Secondary antibody solutions contained 1:1000 dilutions of
Goat Anti-Mouse IgM-AP (SouthernBiotech 1021-04) or Goat Anti-Mouse IgG1-AP
(SouthernBiotech 1070-04). Washes were performed using PBS with 0.05% Tween 20. Wells
were developed in developing buffer (0.1M Glycine, 1mM Zinc Chloride, 1 mM Magnesium
Chloride) with 1 mg/ml PNPP substrate (ThermoFisher 34047) and OD 405nm was read using a
Spectramax M3 plate reader (Molecular Devices).
5.17 Elicitation of VSG-specific polyclonal IgM antisera
Female C57BL/6J mice were injected i.p. with live trypanosomes in 100-200ul HMI-9. For
Chapter 2, injections contained 1-2 x 104 WT-VSG2 trypanosomes. For Chapter 3, injections
contained 1 x 103 VSG3WT or VSG3S317A-expressing trypanosomes. After 4 days, infections were
cleared with 250ng berenil/mouse injected i.p., and berenil treatment was repeated after 24
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hours. Clearance was necessary to prevent animals from succumbing to infection prior to
developing significant antibody titers. On day 8 post-injection, blood was collected via cardiac
puncture, and serum was separated from whole blood using Microtainer serum collection tubes
(BD 365967).
5.18 Flow cytometry-based IgM binding assays
5.18.1 Chapter 2
Flow cytometry samples were prepared as described in section 5.9.2, except antibody binding
was done in two steps: (1) VSG2-specific polyclonal IgM antisera, diluted 1:100 in mouse serum
(Mouse Reference Serum, Bethyl Laboratories, RS10-101). (2) 1:500 dilution of Goat AntiMouse IgM-FITC (Southern Biotech 1021-02) in HMI-9. Samples were incubated for 10 min in
each antibody solution and washed once with HMI-9 after each binding step. Control samples
labeled with monoclonal anti-VSG2-Alexa647 were prepared using a single antibody incubation
step. For data analysis (using FlowJo software), trypanosome populations were gated via forward
and side scatter, then dead cells were excluded by gating cells negative for Propidium Iodide
staining.
5.18.2 Chapter 3
Same as above except: (1) Primary staining was performed with VSG3WT or VSG3S317A-elicited
polyclonal IgM antisera diluted in HMI-9 (dilutions indicated in figure legends), and (2)
secondary staining was performed with a 1:1000 dilution of goat anti-mouse IgM-FITC
(SouthernBiotech 1021-02) in HMI-9.
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5.19 Development of mathematical IgM-VSG coat binding interface model
To approximate the binding “footprint” of a pentameric IgM molecule on the VSG coat, the VSG
coat was first modeled as a regularly spaced hexagonal grid, as has been shown in previous
studies181. A regular hexagon of height h has 6 sides of length equal to (h / 31/2). A hexagon with
a height of 40 nm (the upper estimate of the diameter of an IgM molecule) thus has sides of
length ~23.1 nm. If such a hexagon has 5 VSG homodimers on each side, they will be equally
spaced at ~5.8 nm (23.1 nm / 4 inter-homodimer spaces), a value extremely close to previously
estimated homodimer spacing (5.7 nm spacing with a random displacement up to 0.5 nm)181.
Filling this hexagon with additional VSG homodimers at the same spacing, we estimated that 61
VSG homodimers (or 122 VSG monomers) would be within reach of a single IgM with a 40 nm
diameter (Fig 2.12b and c). The same calculations were performed for IgM with a 30 nm
diameter: 30 nm / 31/2 gives a side length of ~17.3 nm. Assuming 4 VSG homodimers on each
side, they will again be equally spaced at ~5.8 nm (17.3 nm / 3 inter-homodimer spaces). Filling
this hexagon results in 37 VSG homodimers (or 74 VSG monomers) within reach of a single
IgM with a 30 nm diameter.
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5.20 Primer and UTR sequences
Primers (Sequences 5’->3’)
JPC1_UniqueFor: TATAAGATCTGCGGCCGCGAGTAAGTAAGTTGGAGCGCAC
JPC2_UniqueRev: ATATCTCGAGGCGGCCGCCATGCTGTCGGTTGTCGGACTTGG
JPC3_pUC19For: TATACTCGAGCCGGGAGCTGCATGTGTCAGAGG
JPC4_pUC19Rev: ATATAGATCTTCGTTCGGCTGCGGCGAGCGG
JPC18_GibsonP2For:
GGGAGGACTAACACAATGAATACGGTTTACACCGGTGGGCTGCACGCGCCTTCGAG
TTTT
JPC19_GibsonP2Rev:
TGACATTACCATTCCGGTACTGTTGGTAAAATGCCTTCCAATCAGGAGGCCCGGCTT
TTC
JP09_VSG221_For: ATGCCTTCCAATCAGGAGGCC
JPC24_GibsonP3221UTR_Rev:
GACTGTCTGATTGTCTAGAAATATTTTCTGGCAGGGCACAGCAAGGTCTTCTGAAAT
TCATGT
JP11_ACT5UTRStart_For: GGGCACAGCAAGGTCTTCTGA
JPC22_GibsonP5Rev:
CGTTTGTTATCTATGCAGTATTCTGCAGGCGTGATGAAGATGCAGATAGATGGCATA
GAT
JPC26_GibsonP3221UTR_For:
GGGAGGACTAACACAATGAATACGGTTTACATTGCATTTGGACACCGCTATACATAT
GTT
JPC31_JP07P2_For:
GGGAGGACTAACACAATGAATACGGTTTACGTGCTCAAGCTGTGTAGCGCACGCGT
TTCC
JPC32_JP07P2_Rev:
AGCCCGAAAACATAAACTCAACTGCAACGAATGCCTTCCAATCAGGAGGCCCGGCT
TTTC
JPC20_GibsonP3Rev:
CCTCTTTGGCTTGCAGTTTTGCTTTTTTAAGATCCTGCCCATTTAGTTGGCTTTTCCCT
T
JP10_Ald3UTR_For: GATCCTGCCCATTTAGTTGGC
JPC21_GibsonP4Rev:
GCCACTACAAGTTGGTTTCCTTCCCCTGCAGGGCACAGCAAGGTCTTCTGAAATTCA
TGT
Procyclin UTR (mod) sequence
ACCGGTGGGCTGCACGCGCCTTCGAGTTTTTTTTCCTTTTCCCCATTTTTTTCAACTTG
AAGGGTACCCTTCAATTACACCAAAAAATAAAATTCACAAACTTGGAATTCCTTTGT
GTTACATTCTTGATCGCTCGCACTGACATTACCATTCCGGTACTGTTGGTAAA
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